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ABSTRACT 
SHERKET PETERSON: Defining the Structural Cues within Heparan Sulfate that Direct 
Heparanase Cleavage 
(Under the direction of Jian Liu) 
 
Heparanase is a glucuronidase that cleaves heparan sulfate in a variety of cells and 
tissues. The depolymerization of HS by heparanase results in smaller fragments of variable 
sizes that bind and modulate the functions of a multitude of proteins, including growth 
factors and their receptors, chemokines, enzymes, and extracellular matrix proteins. 
Identification of precise structural features within HS that direct heparanase cleavage has 
been hindered by the heterogeneity of substrates, the lack of techniques to synthesize 
structurally defined oligosaccharides or polysaccharides with site-specific sulfation, and a 
lack of large quantities of pure heparanase. Here, we report how advances in the 
methodology for synthesizing substrates with defined sulfation types has allowed us to 
identify specific sulfation types as well as residues that may direct heparanase cleavage. 
Utilizing chemo-enzymatically synthesized polysaccharide substrates with unique sulfation 
patterns, we were able to dissect that heparanase cleaves the linkage between a GlcUA unit 
and an N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo group. In 
addition, heparanase cleaves the linkage of a GlcUA unit and N-sulfo glucosamine unit with 
a 2-O-sulfated GlcUA residue, not a 2-O-sulfated IdoUA residue, in proximity. We also 
discovered that the polysaccharide with repeating disaccharide units of IdoUA2S-GlcNS 
inhibits the activity of heparanase. Moreover, the utilization of a selective library of 
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oligosaccharides coupled with ESI-MS analysis and large quantities of a pure enzyme 
provided the opportunity to examine the substrate specificity of heparanase in greater detail.  
We determined that heparanase utilizes the GlcNAc6S/GlcNS6S at the nonreducing end to 
direct the cleavage pattern. Moreover, heparanase depolymerizes the oligosaccharides 
utilizing a non-processive method. Our data reveals for the first time that heparanase is 
regulated by two main factors; the primary factor is heparanase recognition of different 
sulfation types with its non-processive mode of action having a secondary role. These 
findings advance the understanding of the substrate specificity of heparanase and reveal a 
unique control mechanism for the action of heparanase. Moreover, our result advances the 
understanding of the regulation of HS biosynthesis and the intimate relationship between HS 
and heparanase.   
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Chapter I  
INTRODUCTION 
Section 1. Structure of heparan sulfate 
Heparan sulfate is a ubiquitous macromolecule present in animal tissues [1]. It belongs to the 
glycosaminoglycan (GAG) family of natural products. In addition to HS, the family consists 
of chondroitin sulfates, keratan sulfate and hyaluronic acid. The members of this class of 
macromolecules differ in the structures of the disaccharide repeating units as well as the 
number of sulfo groups on the polysaccharide, with the exception of hyaluronic acid, which 
contains no sulfo groups. HS contains a disaccharide-repeating unit of glucosamine (GlcN) 
and glucuronic/iduronic acid (GlcUA/IdoUA) residues with various sulfo groups (Figure 1). 
The majority of GlcN residues are modified with either N-acetyl or N-sulfo groups. However, 
1–7% of GlcN in HS is present in N-unsubstituted glucosamine (GlcNH2) [2]. HS is the most 
extensively studied GAG, demonstrating a variety of biological functions that range from 
regulating blood coagulation [3] and assisting viral infections [4] to regulating cell growth 
[5]. Due to the diverse functions of HS and heparin, the possibility of exploiting its 
anticancer, anti-inflammatory and antiviral activities, in addition to its anticoagulant activity, 
is generating considerable interest. 
 Heparin, a special form of HS, is a commonly used anticoagulant drug. HS is 
structurally similar to heparin, and they are synthesized by the same biosynthetic 
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mechanism. Heparin, a highly sulfated version of HS, contains 2.6 sulfo groups per 
disaccharide on average, while its HS counterpart contains about 0.6. Also, some 80% of the 
hexauronic acid units of heparin are IdoUA, while only about 20% of hexauronic acid units 
of most HS are IdoUA. Furthermore, in vivo, heparin is only found in intracellular vesicles of 
connective tissue mast cells, while HS is present in a variety of cell types.  
 
Figure 1.  Structures of disaccharide repeating units of HS and commonly found monosaccharides. 
Sulfation (R = -SO3) at Carbon 6 (known as 6-O-sulfo glucosamine) of glucosamine is common. Sulfation at 
Carbon-2 of iduronic acid (known as IdoUA2S) is common. Sulfation at Carbon-3 of glucosamine (known as 3-
O-sulfo glucosamine) is rare. Both N-acetyl (R’ = acetyl, GlcNAc) and N-sulfo glucosamine (R’ = -SO3, 
GlcNS) are common. N-unsubstituted glucosamine (R’ = -H, GlcNH2) is a low abundance component. 
 
Although the fine structure of heparin differs significantly from that of HS, the global 
structures of these polysaccharides are surprisingly comparable. Similarly, heparin and HS 
are biosynthesized as HS proteoglycans (HSPG), comprising a core protein covalently 
attached to polysaccharide side chains.   Depending on the amino acid sequences of the core 
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proteins, HSPG includes syndecans, serglycin, glypicans, agrin and perlecans. The major cell 
surface HSPGs are the syndecans and glypicans,[6, 7] and the major ECM HSPGs are 
perlecan and agrin [8]. The core protein carrying two or three HS chains can be anchored to 
the cell membrane via the transmembrane domain, such as syndecan, or via the 
glycosylphosphatidylinositol (GPI)-linked motif, such as glypican. The core protein 
determines the location of HS in a specific tissue and may play an important role in 
enhancing HS effects. In addition, the core protein is directly involved in growth factor 
binding and can participate in cellular signal transduction [9]. The biological functions of 
HSPG are predominantly determined by the HS side chains that can bind a variety of protein 
ligands and thereby influence many biological processes.  HS ability to regulate a variety of 
functions is a result of its structural heterogeneity via sequential enzymatic modifications. 
 
Section 2. Biosynthesis and regulation of HS 
Biosynthesis of HS 
The biosynthesis of HS occurs mainly in the Golgi apparatus and involves a complex 
set of specialized enzymes (Figure 2) [10]. Biosynthesis of the HS polysaccharide chains 
takes place in three phases: chain initiation, polymerization, and polymer modification. Chain 
initiation begins with the stepwise addition of a xylose residue, two galactose residues and a 
GlcUA residue [11]. This tetrasaccharide linkage region is attached to specific serine 
residues of the core protein containing a structure of β-xylose-(1,4)-β-galactose-(1,3)-β-
galactose-(1,3)-β-glucuronic acid. HS is then synthesized as a linear copolymer of GlcUA 
and GlcNAc, which is known as the polysaccharide backbone as shown in Figure 2. A series 
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of polymer modifications are then carried out by numerous biosynthetic enzymes, including 
glucosaminyl N-deacetylase/N-sulfotransferase [12], which converts the GlcNAc unit to a 
GlcNS unit. A specific isoform of N-deacetylase/N-sulfotransferase (NDST-2), highly 
expressed in mast cells,  is proposed to be involved in synthesizing heparin, but not HS [13]. 
After N-sulfation, C5-epimerase (C5-Epi) converts a GlcUA unit to an IdoUA unit. The 
resulting polysaccharide is further modified by 2-O-sulfotransferase (2-OST), 6-O-
sulfotransferases (6-OST) and 3-O-sulfotransferases (3-OST) to introduce the 2-O-sulfo 
group to IdoUA/GlcUA and the 6-O-sulfo and 3-O-sulfo groups to the GlcN unit [14]. The 
enzymatic reactions do not continue to completion, thus resulting in substantial sequence 
diversity within HS [7]. 
 
Figure 2. Biosynthesis of HS. HS biosynthesis begins with the alternating addition of a GlcUA and GlcNAc to 
construct the backbone. This allows a dual function enzyme named N-deacetylase/N-sulfotransferase to remove 
acetyl groups and add sulfation to the amine group of the glucosamine. This gives way to C5 epimerase which 
alters the carbon at the 5
th
 position of the uronic acid changing this structure from GlcUA to IdoUA. This opens 
the door to 2-O-sulfotransferase which transfers sulfation to the 2-OH position of the uronic acid.  Now, 6-O-
sulfotransferase and 3-O-sulfotransferase are now able to add sulfation to the 6-OH or 3-OH position of the 
glucosamine. 
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Regulation of the sulfation patterns in HS 
  HS structural complexity is regulated by the HS biosynthetic enzymes. Since HS 
biosynthesis is not a template-driven process, the substrate specificities of the biosynthetic 
enzymes dictate the structures of the final HS product. These biosynthetic enzymes exhibit 
their substrate specificities at two different levels: the regioselectivity of the residue at the 
modification site (monosaccharide level) and the sulfation patterns around the modification 
site (oligosaccharide level). The regioselectivity at the modification site for a given HS 
sulfotransferase is nearly exclusive [15-18]. For example, 6-OST recognizes a GlcNS or 
GlcNAc residue and specifically transfers the sulfo group to the 6-OH position to form 
GlcNS6S [or 6-O-sulfo N-acetylated glucosamine (GlcNAc6S)]. 
HS structure is also regulated by distribution of GlcNS residues. The synthesis of 
GlcNS by NDST is the first step of a series of biosynthetic modifications. It is known that the 
presence of the GlcNS residue is critical for all subsequent modifications during the 
biosynthesis of HS. In other words, a cluster of GlcNS residues determines the location of 
other O-sulfations and epimerization of GlcUA. These clusters form so-called ‘‘sulfated 
domains of HS,’’ which dictate the majority of their functions [19]. Results from cell-based 
assays demonstrated that cells lacking NDST-1 or NDST-4 synthesize undersulfated HS [20, 
21]. Carlsson and colleagues demonstrated that NDST-1 has the ability to form clusters of 
GlcNS residues, suggesting its role in the distribution of GlcNS to the overall structure of the 
final HS [22]. Targeted gene deletion of NDSTs also point to the physiological significance 
of GlcNS in the biosynthesis of HS. For example, NDST-1 null mice display dramatically 
reduced amounts of sulfated HS and die shortly after birth [23]. Studies on the conditional 
knock out of the NDST-1 gene revealed that GlcNS is essential in synthesizing the HS that 
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regulates L-selectin- and chemokine-mediated neutrophil trafficking [24]. In contrast, mice 
deficient in NDST-2 are viable but show a lack of heparin synthesis in mast cells [25]. The 
distinct phenotypes of NDST-1 and -2 knockout mice strongly suggest that unique GlcNS 
distribution directs the synthesis of HS with specific physiological functions. 
Another regulation of different sulfation patterns is via different HS biosynthetic 
enzyme isoforms. It has been hypothesized that cells regulate expression levels of different 
isoforms in order to synthesize the HS with defined saccharide sequences to achieve unique 
biological functions [26]. HS biosynthetic enzymes are present in multiple isoforms, with the 
exception of 2-OST and C5-Epi. NDST is present in four different isoforms, 6-OST is 
present in three and 3-OST in seven. In addition, these isoforms have slightly different 
substrate specificities and unique tissue expression patterns [20, 27-29]. 3-OST isoforms are 
essential for HS synthesis with a variety of saccharide sequences that exhibit different 
functions [30].  For instance, 3-OST-1 sulfates HS to synthesize a product with anticoagulant 
activity, while 3-OST-3 sulfates HS to synthesize a product that serves as an entry receptor 
for herpes simplex virus (HSV). 3-OST-5 can synthesize HS with either anticoagulant 
activity or an HS that can serve as an entry receptor for HSV. Various isoforms of 6-OST are 
important for building the HS that bind to FGFs and FGFRs, although the substrate 
specificities among 6-OSTs are not experimentally distinguishable [31, 32]. 
 
Physiological functions of HS 
One method to study the structure and function of HS that carry different sulfation 
patterns in vivo is to conduct gene knockout experiments in various organisms of HS 
biosynthetic enzymes. This approach has provided novel insights into the functional roles of 
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these enzymes in numerous processes. The results from knockout experiments should be 
explained with caution because the lack of sulfation in these knockout organisms can be 
compensated by an increase in other sulfation types as the case demonstrated in Drosophila 
[33]. 
The importance of Exostosin genes (EXT1 and EXT2), which encode 
glycosyltransferases or HS polymerases for the synthesis of HS backbone, has been shown in 
several knockout mouse studies. Specifically, EXT1 and EXT2 enzymes function as a hetero-
oligomeric complex to polymerize the HS backbone [34]. The phenotype expressed by EXT 
null mice are embryonic lethal due to the shorter HS chains linked to the core protein [35]. 
Subsequently, Strickens et al. observed similar results in an Ext2 null mouse model [35]. 
While a complete loss of both EXT genes can be lethal, partial loss in either isoform results 
in bone exostosis, which is a genetically heterogeneous human disease characterized by bony 
outgrowths near the ends of the long bones [35, 36]. 
 Dramatic effects on the HS sulfotransferases and C5-Epi were also observed for 
enzymes defective in modification steps. NDST is a bifunctional enzyme that removes the 
acetyl group from GlcNAc residues and transfers a sulfo group to the deacetylated GlcN [37, 
38]. Silencing of NDST alters the HS structure owing to changes in reduced C5-
epimerization and O-sulfations [39].  Mice lacking NDST-1 exhibit severe defects such as 
abnormal brain and face development, including cerebral hypoplasia, lack of olfactory bulbs, 
eye defects, and axon guidance errors [40].  In addition, NDST-1 has also been shown to be 
essential for normal respiratory function [23].  The phenotypes observed in NDST-1-null 
mice are thought to be a result of NDST-1’s ability to modify signaling in hedgehog, FGF, 
and Wnt pathways [40, 41]. Of the four isoforms of NDST, NDST-1 is presumed to be 
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essential. This reasoning is based on studies of NDST-2 null mice in which the only 
abnormality seen was in connective tissue type mast cells [39]. Further, NDST-3 -knockout 
mice are fertile and exhibit only minor hematological and behavioral phenotypes [42]. 
Therefore it is believed that other NDST genes can compensate for all isoforms except for 
the loss of NDST-1. 
C5-Epi converts D-GlcUA to L-IdoUA units [43, 44].  Li et al. observed that the HS 
isolated from C5-Epi knockout mice lacked the IdoUA unit and thus a change from the 
predominantly sulfated disaccharide unit IdoUA2S-GlcNS to GlcUA-GlcNS6S. The lack of 
C5-Epi also produced mice with a lethal immature lung phenotype, abundant skeletal 
abnormalities, and kidney agenesis. It is interesting to note that the phenotypes displayed by 
C5-Epi knockout mice are similar to those observed in 2-OST null mice. 
 HS 2-OST catalyzes the transfer of a sulfo group to the C2 position of GlcUA or 
preferentially IdoUA to form 2-O-sulfo glucuronic acid (GlcUA2S) and 2-O-sulfo iduronic 
acid (IdoUA2S), respectively [45, 46]. The 2-OST-knockout mice demonstrated a complete 
failure of kidney development and several skeletal abnormalities [47, 48]. However, in 
contrast to C5-Epi-null mice, the loss of 2-O-sulfation in mutants is compensated for, in 
terms of charge, by a 13% increase in 6S and a 9% increase in NS in NS sulfated domains 
[49]. Furthermore, the 2-OST-null mice survive until birth, unlike C5 epimerase mutants, but 
die soon after due to kidney agenesis [46].  In Caenorhabditis elegans, 2-OST has been 
determined to be essential for axon migration/guidance and nervous system development [50, 
51]. Dependence on 2-O-sulfation is notably less critical in Drosophila FGF signaling. It was 
suggested that the 2OST mutant synthesizes HS with a higher level of 6-O-sulfation, which 
may compensate for the reduced 2-O-sulfation in Drosophila [33]. 
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HS 6-OST catalyzes the transfer of a sulfo group to the C6 position of GlcNS to form 
GlcNS6S,[52] which has been shown to have functional consequences for several proteins. 
Mice deficient in 6-OST-1 had growth retardation, aberrant eye and lung morphogenesis, and 
impaired placenta function and died at or soon after birth [53].  Habuchi et al. observed that 
6-O-sulfated residues participate in Wnt2 recognition and that HS 6-OST-1 is considerably 
less important than NDST-1 in controlling lung development and function. In spite of this 
finding, more studies are needed to resolve the individual roles of 6-OST isoforms. 
HS 3-OST transfers a sulfo group to the 3-OH position of the glucosamine unit to 
form 3-O-sulfo N-sulfo glucosamine (GlcNS3S). The 3-O-sulfation is essential for binding to 
gD [54] and FGF-7 and its receptor [55]. The 3-O-sulfation also plays a critical role in 
binding to AT, exhibiting the anticoagulant activity [18]. The essential role of 3-O-sulfation 
for synthesizing anticoagulant HS has led to the hypothesis that 3-OST-1 null mice would 
demonstrate a procoagulant phenotype and reduced antithrombin binding HS [56].  However, 
mice lacking 3-OST-1 do not exhibit a procoagulant phenotype. These results can be 
explained by the fact that other isoforms of 3-OST, such as 3-OST-5, may take the place of 
3-OST-1 to synthesize a low level of anticoagulant HS [57].  These mice displayed a range of 
unanticipated abnormalities like spontaneous eye degeneration, aberrant cardiovascular 
response to anesthesia, reduced fertility, postnatal death, and intrauterine growth retardation. 
The levels of 3-O-sulfation, the products modified by 3-OST, are typically low in the HS 
isolated from natural sources [58]. There are numerous 3-OST isoforms depending on the 
organisms. It has been widely speculated that 3-O-sulfation participates in very specific 
biological processes in addition to regulating the blood coagulation. In particular, the roles of 
3-O-sulfation in regulating embryonic development have been explored. Using RNAi 
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technique, Kamimura and colleagues concluded that knockout Hs3stB, which is the 3-OST-3 
gene in humans and mouse, resulted in neurogenic phenotype due to the effect on Notch 
signaling pathway in Drosophila [59].  In addition, the expression of seven 3-O-
sulfotransferase isoforms exhibit distinct patterns at various developmental stages in 
zebrafish [60]. 
 
 
Section 3. Biological function and potential therapeutic application of HS 
 
HS is expressed ubiquitously on the cell surface and in the extracellular matrix 
(ECM), where it acts as an important biological mediator of various cellular events. HS 
interacts with matrix components such as fibronectin, laminin, and collagen to maintain the 
structural integrity of the ECM. In addition, HS sequesters cytokines and growth factors to 
the ECM [7, 61, 62].  Consequently, HS has roles in regulating angiogenesis, metastasis, 
inflammation, and wound healing. Heparin, a highly sulfated version of HS, is commonly 
used to treat thrombotic disorders. Furthermore, biochemical and clinical evidence suggest 
that heparin also has anticancer and anti-inflammatory activities.  Hence, the diverse 
functions of HS and heparin as well as it therapeutic potential has attracted considerable 
interest. 
 
Heparin in malignancies 
 Thromboembolism is a frequent complication of malignancies; often, spontaneous 
thrombosis is an indication of occult cancer [63-65].  Tumor cells release procoagulants, 
including cysteine proteases and tissue factors that directly activate factors X and VII. The 
interaction between immune and malignant cells activates platelets, factor XII, and factor X, 
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leading to thrombin production and thrombosis. This interaction also causes the release of 
tumor necrosis factor, interleukin-1, and interleukin-6. These mediators initiate endothelial 
damage and create a thrombogenic vascular in surface [66]. Heparin’s anticoagulant 
properties are useful against thrombosis in cancer. Briefly, heparin may directly influence 
tumor cell behavior by interacting with integrins to interfere with tumor cellular adhesion and 
binding to growth factors [67]. In addition, heparin prevents cancer cell interaction with 
platelets and endothelial cells by inhibiting selectin binding [68]. Low molecular weight 
heparins (LMWH) are suggested to regulate angiogenesis by inhibiting matrix-degrading 
enzymes [69, 70]and have been utilized in prophylaxis and treatment of thromboembolic 
disease in patients with malignancy. 
Clinical evidence for heparin use as an antimetastatic and antiangiogenesis agent is 
less conclusive and shows dose-limiting anticoagulant side effects [62].  A systemic review 
by Tagalakis and colleagues revealed heparins (predominantly LMWH) may improve the 
survival of patients with small cell lung cancer and advanced malignancy with more 
favorable prognoses. More research is necessary to elucidate which type of cancer and stage 
would benefit most from heparin therapy [71].  Currently, the American Society of Clinical 
Oncology and American College of Chest Physicians do not recommend anticoagulants to 
improve survival in patients who have cancer but are not at risk for venous thromboembolism 
[72].  However, the Society encourages patient participation in clinical trials designed to 
evaluate anticoagulant therapy as an adjunct to standard anticancer therapy [73]. 
Although heparins have been shown to be advantageous in cancer patients, the 
anticoagulant properties of heparin and heparin-like compounds limit the antitumor 
applications of therapy. If the anticoagulant activity of heparin could be separated from 
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antiangiogenic and anti-metastatic properties, a novel anticancer agent could possibly be 
developed. However, patients may still require anticoagulation as a result of cancer and 
chemotherapy hypercoagulable effects. The development of new antiangiogenic and anti-
metastatic compounds that are structurally or functionally related to non-anticoagulant 
heparin could serve as a promising cancer therapy. 
 
Heparin as an anti-inflammatory therapy 
A hallmark of chronic inflammatory diseases, such as rheumatoid arthritis, asthma, 
inflammatory bowel disease, and psoriasis, is the unwarranted infiltration and accumulation 
of inflammatory cells into affected organs. These events can lead to tissue damage and 
cellular remodeling. Heparin has been shown to reduce and even inhibit leukocyte 
accumulation in inflamed skin [74], brain [75], lung [76], and hyper-responsive bronchial 
tissue in animal models. Furthermore, its anti-inflammatory effect has been shown to be 
distinct from its anticoagulant properties [12, 77]. In addition, a study by Ahmed et al. in the 
New England Journal of Medicine showed that heparin could reduce inflammatory cell 
activation and accumulation in lung tissue and thereby improve respiratory function. Inhaled 
heparin has provided evidence of efficacy in exercise-induced asthma treatment. Partial 
thromboplastin times were tested at baseline and following a test dose of inhaled heparin in 
12 patients. These patients were then pretreated with 1000 U/kg heparin, 20 mg of cromolyn 
sodium, or placebo followed by an exercise challenge. Heparin did not alter the pH or the 
bronchorestrictor response to histamine but did prevent exercise-induced asthma [78].  It has 
been hypothesized that LMWH may also attenuate exercise induced bronchoconstriction. 
Another study with 13 asthmatic patients treated with enoxaparin or unfractionated heparin 
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revealed enoxaparin prevents exercise-induced bronchoconstriction in a dose-dependent 
manner independent of its effect on plasma Xa activity. However, enoxaparin did not modify 
the bronchoconstrictor activity of methylcholine [79]. 
Nevertheless, topical administration of heparin may be effective for limiting 
inflammatory events in allergic rhinitis. In a study with 10 patients, the effect of 4 ml of 
intranasal unfractionated heparin at 3750 U/ml was compared with placebo in a double-blind, 
randomized trial. Patients treated with unfractionated heparin had reduced symptom scores, 
eosinophil counts, and eosinophilic cationic protein levels in the nasal lavage following 
allergen challenge [80]. 
Heparin has been evaluated in small clinical trials and individual cases as a treatment 
for inflammatory bowel disease [81, 82]. The beneficial effects of heparin in inflammatory 
bowel disease include attenuation of the prothrombotic effects of the disease, prevention of 
thrombotic occlusion and subsequent intestinal infarction, enhancement of endothelial barrier 
function, reduction of inflammatory cytokines, and inhibition of neutrophil diapedesis in 
intestinal mucosa [83].  In addition, heparin has been reported to be effective in case reports 
of Crohn’s disease, but this evidence has been limited. In three uncontrolled studies with 39 
patients with severe, steroid-resistant ulcerative colitis and 4 patients with Crohn’s disease, 
28 of these patients experienced remission following heparin administration [84].  A recent 
Cochrane review recommended against the use of unfractionated heparin and LMWH in the 
treatment of active ulcerative colitis because of lack of evidence and risk of bleeding with 
heparin  administration [85].  However, Chande and colleagues felt trials of unfractionated 
heparin in mild ulcerative colitis may be warranted. 
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Section 4. HS degradation and heparanase molecular properties 
HS is a highly sulfated polysaccharide that is expressed ubiquitously on the cell 
surface and in the ECM. HS occurs as a proteoglycan in which two or three HS chains are 
attached to a core protein. These HS chains possess various types of modifications (discussed 
in Section 2) that allow HS to bind a variety of ligands and regulate an array of functions, 
such as angiogenesis, tumor metastasis, developmental processes, and blood coagulation. 
Under normal physiological conditions, HS interacts with fibronectin, laminin, and collagen 
to help maintain the structural integrity of the ECM and participates in cell-cell and cell-
ECM interactions. Furthermore, HS has the ability to bind a multitude of proteins (i.e., 
growth factors, chemokines, lipoproteins, enzymes, etc.) and act as a storage depot by 
preventing these proteins from binding to their respective receptors (Figure 3).  
 
 
Figure 3. HS regulates cellular signaling. HS structure allows it to bind a variety of ligands. HS prevents its 
binding partners from interacting with their respective receptors. In turn, this prevents HS-binding partner-
receptor complexes from forming thereby preventing cellular signaling. 
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In turn, this allows HS to regulate cellular signaling as well as accessibility, function, and 
mode of action of its binding partners.  It is because of the important and multifaceted roles 
of HS in cell and tissue physiology that allows the cleavage of HS to have such a significant 
effect within the body [86]. Therefore, enzymatic degradation of HS is expected to 
profoundly affect fundamental biological processes, such as pregnancy, morphogenesis, 
inflammation, neurite outgrowth, angiogenesis, and cancer metastasis [87].  
 
Heparanase history 
 Heparanase is an endo-β-glucuronidase that cleaves HS in a variety of normal and 
malignant cells and tissues, such as placenta, platelet, skin, fibroblast, melanoma, lymphoma, 
carcinoma, hepatocytes, Chinese hamster ovary (CHO) cells, keratinocytes, neutrophils, 
macrophages, T and B lymphocytes, mast, and endothelial cells [1, 86, 88-96].  The journey 
for identifying and characterizing heparanase has been long and challenging. The first 
mention of heparanase in literature occurred in 1975 when Ogren and Lindahl [97] reported 
the cleavage of heparin by an enzyme isolated from the mastocytomas of tumor bearing 
mice. Due to the lack of a simple and reliable assay to quantify heparanase activity, 
molecular probes, antibodies, and a low abundance of heparanase in cells, the cDNA of 
heparanase remained unidentified for another two decades. In 1999, cloning of the 
heparanase gene was reported by several groups [89, 91, 94, 96] from human and other 
species. In the recent years, progress in the field has led to the discovery of new information 
which have expanded our understanding of heparanase as well as its function and 
significance in normal physiology and pathology. 
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Proheparanase and heparanase 
It is now known that human heparanase cDNA contains an open reading frame of 
1629 bp that encodes for a 543 amino acids [96]. Sequence analysis revealed that human 
heparanase is highly conserved, with similar sequences found in chicken [98], rat [99], 
mouse [100], cow [101, 102],  Spalax or subterranean mole rat [103], mollusks, and zebra 
fish . Surprisingly, human heparanase has the highest homology with bovine and Spalax 
heparanase with a homology percentage of  86.1% and 84.5%, respectively [87]. However, 
the gene has not been identified in Drosophilia melanogaster or Caenorhabditis elegans, 
which suggest that HS cleavage in these organisms, may be carried out by a different 
enzyme.  
Heparanase has a similar structure to that of a cysteine protease. To date, heparanase 
is known to exist in three forms: a pre-proheparanase, proheparanase, and heparanase (Figure 
4). Heparanase is synthesized in the cell as an inactive precursor composed of 4 distinct 
domains: an N-terminal domain of variable size, a large subunit, a small subunit, and a linker 
region between the large and small domains. The inactive precursor of heparanase, known as 
pre-proheparanase, is initially synthesized as a latent 65kDa precursor.  When the N-terminal 
signal peptide (Met
1
-Ala
35
) [96] of the pre-proheparanase is removed, the new form of 
heparanase becomes known as proheparanase. However, activation of heparanase cannot be 
induced until it undergoes further processing by cathepsin L before it can exist in its mature 
form [104]. Cathepsin L is a lysosomal cysteine proteinase that plays a major role in 
intracellular protein catabolism. Proheparanase must undergo proteolytic activation by 
cathepsin L to excise the intervening 6kDa (Ser
110
-Gln
157
) linker region of heparanase. 
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Figure  4. Heparanase processing forms. Heparanase is synthesized as a 65kDa precursor (pre-proheparanase) 
with 6 N-glycosylation sites (blue trophies). Pre-proheparanase becomes proheparanase when the signal peptide 
is removed. After proteolytic activation by cathepsin L, the linker region is removed and the 50 kDa and 8 kDa 
subunit noncovalently associate to form mature heparanase. 
 
Removal of the linker region allows the 50 kDa (Lys
158
-Ile
543
) and 8 kDa (Gln
36
-Glu
109
) 
heterodimer to noncovalently associate in an active conformation known as heparanase 
[105]. This structural complexity tightly regulates heparanase activity. The detailed 
processing of heparanase will be discussed in a later section entitled “Heparanase cellular 
processing.” 
 To date, there is no published crystal structure of heparanase or any of the members 
of other enzymes of Carbohydrate Active enZYmes (CAZy) family 79. CAZy is a database 
that describes the families of structurally-related catalytic and carbohydrate-binding 
functional domains of enzymes that degrade, modify, or create glycosidic bonds 
18 
 
(http://www.cazy.org/).  Multiple-sequence alignment approaches in combination with 
secondary structure predictions indicate that heparanase contains sequences that are 
homologous to family 10, 39, and 51 of the clan A glycosyl hydrolases [90]. Several sources 
[90, 106] including a predicted three dimensional structure of active [106] heparanase  
revealed that heparanase is organized into two structural domains: a catalytic domain with 
(α/β)8 triosphosphate isomerase (TIM)-barrel fold followed by a β-sandwich C-terminal 
domain (Figure 5A and 5B). The C-terminal domain is composed of 8 β-strands, one of 
which is contributed by the 8 kDa subunit (yellow), arranged in two sheets from the 50 kDa 
subunit (blue and orange), which are connected by an unstructured, flexible loop (arrow) 
(Figure 5C). The C-terminal domain has been shown to be responsible for the heparanase 
secretion and the nonenzymatic functions of heparanase, such as activation of the Akt 
signaling pathway [106]. The detailed functions of the C-terminal domain will be discussed 
below in “Nonenzymatic effects exhibited by heparanase.” 
 
Figure 5. Three-dimensional model of heparanase. The model, including the 8-kDa (yellow) and 50-kDa 
(gray) protein subunits, amino acids critical for heparanase catalysis (Glu225 and Glu343; red), and heparin 
binding regions (Lys158-Asp171 and Gln270-Lys280;cyan and green, respectively), is shown in the left and 
middle panels. A more detailed structure of the C-domain is shown in the right panel. The model illustrates 
eight β-strands, one of which is contributed by the 8-kDa subunit (yellow), arranged in two sheets 
(blue and orange), which are connected by an unstructured, flexible loop (arrow). 
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Heparanase mechanism of action 
 Currently, there is no crystal structure of heparanase or any of the members of other 
enzymes of CAZy family 79. Therefore, sequence comparisons had to be utilized to indicate 
similarities between heparanase and  family 10, 39, and 51 of the clan A glycosyl hydrolases 
[90] in order to investigate the enzymatic mechanism of heparanase using 3-D models. From 
this data, it has been inferred that heparanase uses a β-retaining hydrolytic mechanism 
(Figure 6). This mechanism involves two carboxylates: Glu
343
 acts as a nucleophile and 
Glu
225
 as an acid/base. Heparanase operates through a two-step mechanism, with each step 
resulting in inversion, for a net retention of stereochemistry [107]. During the first step, the 
nucleophile (deprotonated Glu) attacks the anomeric center of the GlcUA, resulting in the 
formation of a glycosyl enzyme intermediate, with acidic assistance provided by the acidic 
carboxylate. In the second step, the now deprotonated acidic carboxylate acts as a base and 
assists a nucleophilic water to hydrolyze the glycosyl enzyme intermediate, giving the final 
hydrolyzed product [107]. 
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 Figure 6. Mechanism of action of heparanase based on the retention mechanism of a β-glycosidase. Glu343 
acts as a nucleophile to form the glycosyl-enzyme intermediate. The enzyme is then displaced from the 
glycosyl-enzyme intermediate by now deprotonated acidic carboxylate acts as a base (Glu
225
) and water in a 
second step. The second inversion restores the original configuration. 
 
Heparanase cellular processing 
Heparanase proteolytic activation is extensively regulated by its complex processing 
(Figure 7). The process of heparanase proteolytic activation begins when pre-pro-heparanase 
is first targeted to the endoplasmic reticulum (ER) by the signal peptide (Figure 7, step 1). 
This signal peptide is then cleaved by a signal peptidase and pro-heparanase is shuttled to the 
Golgi apparatus (Figure 7, step 2). The pro-form of heparanase subsequently secreted via 
vesicles that bud from the Golgi (Figure 7, step 3). Once secreted, heparanase rapidly 
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interacts with cell membrane heparan sulfate proteoglycans (HSPGs) (such as syndecan 
family members) (Figure 7, step 4). Binding of heparanase to the HSPG is followed by rapid 
endocytosis of the heparanase-HSPG complex (Figure 7, step 5) that appears to accumulate 
in endocytic vesicles such as endosomes (Figure 7, step 6). Conversion of endosomes to 
lysosomes results in a change to a more acidic pH and as a result heparanase processing and 
activation to its mature form (Figure 7, step 7). Heparanase exhibits maximal endo-
glycosidase activity between pH 5.0 to 6.0, and is inactivated at pH > 8.0 [108]. At 
physiological pH, little enzymatic activity is detected, but non-enzymatic functions of 
heparanase may still be preserved. These non-enzymatic functions will be discussed in a later 
section entitled “Non-Enzymatic effects exhibited by heparanase.”  
Based on the predicted amino acid sequence, the 50 kDa subunit of human 
heparanase contains 6 putative N-glycosylation sites at asparagine residue 162, 178, 200, 
217, 238, and 459 [109]. In a study by Simizu et al., Asn
459
 was mutated and the amounts of 
heparanase in the Golgi were reduced compared to WT heparanase. This indicated that 
heparanase glycosylations may affect secretion and ER-to-Golgi transport. However, it is not 
clear if it accelerated retrograde trafficking from Golgi to ER therefore reducing the amount 
of protein in the Golgi. Although glycosylation was shown to be not required for enzymatic 
activity, it has not been shown if the glycosylation sites could affect proper folding or the 
stability of heparanase.  
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Figure 7. The steps to heparanase cellular processing. Pre-proheparanase is targeted to the ER by the SP 
(step 1). After SP cleavage, proheparanase is shuttled to the Golgi (step 2) and then it is secreted via vesicles 
that bud from the Golgi (step 3). Proheparanase rapidly binds to syndecans (step 4) and is endocytosed into the 
cell (step 5). Heparanase is stored in endosome (step 6) until it is converted into a lysosome producing active 
heparanase (step 7). 
 
Heparanase 2 
 To date, heparanase or heparanase-1 is the only known mammalian enzyme capable 
of degrading HS, despite earlier reports of the existence of several HS-degrading enzymes. In 
2000, a heparanase homolog was reported by Mckenzie et al. using the heparanase-1 amino 
acid sequence in a BLAST search of a proprietary human expressed sequence tags (EST) 
database. The heparanase homolog, known as heparanase-2, possessed about 40% identity to 
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heparanase-1 but lacked the ability to degrade HS [110]. As a result of alternative splicing, 
heparanase-2 is predicted to encode three proteins (Hpa2a, Hpa2b, Hpa2c) that range in size 
from 48 to 60 kDa [111].  Until 2010, there was no data reported about the functions of 
heparanase-2. A study by Levy-Adam et al. reported that similar to heparanase, heparanase-2 
is secreted and exhibits a high affinity toward heparin and HS. However, heparanase-2c 
(Hpa2c) does not need to be internalized for activation like heparanase, instead once it binds 
to syndecans it remains on the cell surface for relatively a long period of time [112]. 
Interestingly, Hpa2c inhibits heparanase and its expression correlates with reduced tumor 
metastasis in head and neck cancer patients. More research is needed to uncover the 
specificity of heparanase-2 as well as its mechanism in cancer inhibition. 
 
Section 5. Heparanase involvement in physiology and disease 
Heparanase role in normal development 
 Heparanase is known to play a fundamental role in regulating several 
pathophysiological processes such as tissue remodeling, inflammation, angiogenesis, 
metastasis, and tumor progression. Consequently, there has been a considerable amount of 
studies exploring the role of heparanase in various disease states. However, less seems to be 
known about heparanase and its role in normal physiology.  It is known that heparanase 
exhibits limited expression in human tissues.  Heparanase mRNA is expressed in the 
placenta, lymphoid organs, keratinocytes, and blood platelets [87, 113-115]. Interestingly, in 
the mole rat (Spalax), heparanase is highly expressed in a diverse group of tissues, such as 
the liver, heart, brain, and eye. It is believed that this abundant expression of heparanase 
helps the subterranean mole rat to adapt to underground life and may contribute to the 
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increased density of blood vessels observed in comparison to mammals that reside above 
ground [103].   
 In 2004, homozygous transgenic mice overexpressing heparanase in all tissues were 
generated by Zcharia et al. to characterize heparanase in normal development and tissue 
remodeling. In comparison to the control mice, the mice that had an overexpression of 
heparanase demonstrated a profound decrease in the size of the HS chains as expected. 
Unexpectedly, the mice appeared normal, were fertile, and exhibited a normal life span 
[116]. Furthermore, overexpression of heparanase resulted in defects in kidney function, 
reduced food consumption and body weight, increase in implanted embryos, altered 
phenotype of mammary glands, and accelerated hair growth. Collectively, the 
characterization of the heparanase overexpressing mouse model revealed the involvement of 
heparanase in embryonic implantation, food consumption, tissue morphogenesis, hair growth 
and vascularization [116]. The enzyme also plays a role in wound repair, HS-turnover, and 
immune surveillance [117, 118].   
 Five years later, Zcharia et al. also developed a mouse model with targeted disruption 
of the heparanase gene to further elucidate the biological significance of HS and heparanase. 
Unlike mice with HS biosynthetic enzyme disruption that either die in the early neonatal 
period [39, 48], exhibit renal agenesis [47], or changes in the cytoskeleton or nervous system 
[36], the heparanase knockout were fertile, exhibited a normal life span, and did not show 
any prominent pathological changes [119]. The lack of major abnormalities was surprising 
and attributed to a marked elevation in matrix metalloproteinases (MMP), in particular, 
MMP-2 and MMP-14 in the KO liver and kidney. Moreover, a decrease in the expression of 
MMP-2, 9, and 14 was observed after heparanase transfection and overexpression in MDA-
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MB-231 cells. Thus, this data suggests a co-regulation of heparanase and MMPs. Therefore, 
Zcharia et al. propose that MMPs (2 and 14) which exert some the effects elicited by 
heparanase (over branching of the mammary glands, enhanced angiogenic response) that the 
MMPs can compensate for heparanase, in spite of their different enzymatic substrates [119].  
 
Heparanase in pathophysiological processes 
Heparanase cleaves HS, which is expressed in a variety of cells and tissues. The 
degradation by heparanase results in smaller HS fragments ranging in size from 10 to 20 
sugar units, and these fragments modulate the functions of growth factors and growth factor 
receptors [120]. Therefore, heparanase plays a fundamental role in regulating several 
pathophysiological processes such as tissue remodeling, inflammation, angiogenesis, 
metastasis, and tumor progression. Consequently, there is considerable interest in the 
development of heparanase modulators for the treatment of inflammatory diseases [121], 
neurodegenerative diseases [122], metabolic diseases [123], and cancer [105].  The 
contribution of heparanase to tumor formation, invasion, and metastasis has been extensively 
studied. The level of heparanase is up-regulated in a number of primary tumors such as head 
and neck, pancreatic carcinoma, hepatocellular carcinoma, and several cultured human tumor 
cell lines [124-128]. The overexpression of heparanase has been correlated to an invasive 
phenotype in experimental animals [105]. Furthermore, heparanase has been linked to 
tumorigenesis in a wide array of cancers, such as breast, prostate, and colon [96, 129-138]. 
Thus, there is considerable interest to find inhibitors of heparanase for anticancer drug 
development. Therefore, I will concentrate on heparanase role in tumor progression and 
cancer because it has been more extensively defined.  
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Figure 8. HS degradation by heparanase. Heparanase cleavage of HS leads to the release of active molecules 
bound HS fragments that are able to bind to their respective receptors and induce cellular signaling.   
 
Angiogenesis is defined as the growth of new capillary blood vessels within the body 
and it is essential for healing and reproduction [139]. This complex process is tightly 
regulated by a delicate balance between growth and inhibitory factors. A critical early event 
in angiogenesis is the degradation of the subendothelial basement membrane, followed by 
endothelial cell migration toward the angiogenic stimulus [105]. Hence, heparanase may 
facilitate endothelial cell invasion and sprouting by degrading HS in the basement 
membrane. Briefly, when heparanase degrades HS from the proteoglycan core it releases HS 
fragments that are bound to angiogenic growth factors, such as bFGF and VEGF.  These HS-
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growth factor bound fragments are now able to bind to their respective receptors and this 
creates HS-growth factor-receptor complexes that can lead to the activation of intracellular 
pathways (Figure 8). Thus, heparanase degradation causes cellular invasion, motility, and 
angiogenesis. 
FGFs and FGFRs play critical roles in the control of many fundamental cellular 
processes, such as cell proliferation, differentiation, and migration [140-142]. In particular, 
basic fibroblast growth factor (bFGF) is a heparin-binding mitogenic protein that enhances 
proliferation of a wide variety of cells. Heparanase  expressed by platelets, tumor, and 
inflammatory cells release active bFGF from the ECM and basement membrane as a 
complex with HS fragments [143]. These bFGF-HS complexes released by heparanase 
potentiate bFGF receptor binding and dimerization which is needed to induce signaling [143, 
144]. Furthermore, heparanase overexpression in U87 glioma [145], HT-29 colon carcinoma 
[146], MCF7 [147], human myeloma cells [148], and MDA-MB-231 breast carcinoma cells 
[149] correlated with enhanced xenograft tumor growth and vascularization [87]. Moreover, 
the overexpression of heparanase in a variety of malignant tumor cells resulted in a 3-to-6 
fold increase in VEGF protein and mRNA levels [150]. Thus, given the number of biological 
mediators that interact with HS, heparanase appears to regulate the activity of an array of 
active molecules that act cooperatively or synergistically to promote neovascularization. 
Collectively, this information reveals that heparanase elicits an indirect angiogenic response 
by releasing HS-growth factor fragments. 
 Metastasis is a multistep process that involves tumor cell escape from the primary 
tumor and migration to new locations not adjacent to the primary tumor. Cell dissemination 
can occur by invasion of blood and lymph vessels, or by penetration of the cancer cell into 
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body cavities are spaces surrounding the organs [151]. Cell invasion and metastasis involves 
ECM degradation by the sequential action of several enzymes such as MMPs, serine and 
cysteine proteases, and endo-glycosidases. One of HS most important roles is to interact with 
fibronectin, laminin, collagen, and growth factors to help maintain the structural integrity of 
the ECM. Therefore, cleavage of HS by heparanase can result in disassembly of the 
subendothelial ECM and extravasation of blood-borne cells. Thus, heparanase 
overexpression in tumor cells has been correlated with an invasive phenotype in experimental 
animals [105]. Moreover, elevated levels of heparanase were detected in the urine samples of 
some patients with aggressive metastatic disease [152] and high levels of heparanase were 
detected in the sera of metastatic tumor bearing animals and cancer patients [92]. Mouse 
melanoma (B16-BL6) tumor cell lines possess high levels of endogenous heparanase and are 
known to have high metastatic potential [153]. It was shown by Edovitsky et al., that B16-
BL6 cells transfected with anti-heparanase siRNA resulted in reduced heparanase expression 
and enzymatic activity. Also, lung colonization in an experimental mouse model was 
significantly reduced >90% by anti-heparanase siRNA in comparison to control cells. Thus, 
the association of reduced heparanase levels and altered metastatic properties in cells 
transfected with siRNA indicates that heparanase is fundamentally involved in cancer 
progression. Interestingly, patients with heparanase-positive tumors display a dramatically 
higher rate of local and distant metastasis compared to patients with heparanase-negative 
malignancies. Subsequently, the postoperative survival was inversely correlated with 
heparanase expression [148, 154-157]. Taken together, these data indicate a direct 
involvement of heparanase in basement membrane invasion and metastasis. 
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Non-enzymatic effects exhibited by heparanase 
 Until recently, the involvement of heparanase in cancer was associated with HS 
degradation, which lead to cellular invasion and the release of biologically active molecules 
bound to HS that elicit angiogenic responses. Recent studies have revealed that heparanase 
exhibits non-enzymatic functions associated with signal transduction. This conclusion was 
drawn from data that showed that inactive heparanase (due to a double point mutation in the 
active site of residue Glu
225
 and Glu
343
) exerts non-enzymatic signaling, independent of HS 
cleavage or whether it was overexpressed in transfected cells or exogenously added [150, 
158, 159]. In particular, enzymatically inactive heparanase was shown to enhance Akt 
signaling and stimulate PI3K- and p38-dependent endothelial cell migration and invasion 
[160]. It also promoted VEGF expression via the Src pathway [150]. Also, cell surface 
expression of inactive heparanase was shown to elicit a firm cell adhesion [158]. At the time 
of the above studies (between 2003-2006) it was still unknown if a particular heparanase 
domain was responsible for this non-enzymatic function. It wasn’t until 2009 that it was 
discovered that heparanase non-enzymatic function was a result of the C-terminal domain 
and the TIM-barrel fold was responsible for the enzymatic functions of heparanase. 
 The discovery of the C-terminal domain arose from a 3D prediction of a 
constitutively active heparanase variant [106]. In this enzyme, the 6 kDa linker segment was 
replaced with 3 glycine-serine repeats (GS3), resulting in a constitutively active enzyme 
[161]. Thus, the GS3 construct eliminated the strict requirement of protein secretion for 
proteolytic activation needed by endogenous heparanase. Fux et al. illustrated two things 
with their 3D predicted structure: 1) the TIM barrel fold which was previously anticipated for 
this enzyme and 2) the existence of a C-terminal domain that was not integral part of the 
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TIM-barrel fold. Interestingly, cells transfected with the TIM-barrel construct (amino acids 
36-417) failed to display heparanase enzymatic activity. This suggested that the C-terminal 
domain was required for heparanase activity and possibly needed to stabilize the TIM-barrel 
structure [106]. Notably, the C-terminal domain does not only affect the activity and 
secretion of heparanase, but is also responsible for the signaling function.  While the TIM-
barrel construct alone yielded no Akt activation in comparison to controls, the overexpressed 
C-terminal domain (amino acids 413-543) stimulated Akt phosphorylation.  
 
 
 
 
 
 
Figure 9. C-terminal domain of heparanase. The model illustrates eight β-strands, one of which is 
contributed by the 8-kDa subunit (yellow), arranged in two sheets (blue and orange), which are connected by an 
unstructured, flexible loop (arrow). 
 
It is important to note that the C-terminal domain construct lacked the 8 kDa segment (amino 
acid 36-55) which contributes one beta strand to the β-sandwich structure of the C-terminal 
domain (Figure  9) [106]. However, Akt phosphorylation was increased from 3-fold by the 
C-terminal domain alone to 8-fold with the addition of the 8 kDa segment liked to the C-
terminal domain in comparison to the controls. This conclusion further validates the 
predicted 3D model. A tumor xenograft model also confirmed the C-terminal domain’s role 
in tumor progression. Briefly, xenografts produced by the C-terminal domain expressing 
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cells seemed markedly enlarged compared with xenografts produced by heparanase 
transfected cells, possibly through enhanced angiogenesis [106]. The proangiogenic effect is 
supported by the marked induction of Akt phosphorylation in the primary endothelial cells. 
Their xenograft models illustrated that in some tumor systems (glioma), heparanase 
facilitates primary tumor progression regardless of its enzymatic activity [106]. 
 
Regulation of heparanase 
 Heparanase has a role in a number of normal and pathophysiological functions and 
therefore, must be tightly regulated to prevent potential chaos within the body. Some obvious 
regulators of heparanase activity are seen in the processing and activation of heparanase, 
such as local pH, cellular localization, secretion, and proteolytic activation by cathepsin L. 
Briefly, in order for pre-proheparanase to become mature heparanase, it must undergo a 
complex process as discussed in “Heparanase structure” and “Heparanase cellular 
processing.” Heparanase must not only for-go secretion to be engulfed back into the cell but 
it must also be localized to perinuclear acidic endosomal and lysosomal compartments [98] 
to have the 6 kDa linker proteolytically cleaved by cathepsin L. This yields mature 
heparanase that has restricted activity at physiological pH but displays maximum activity 
between pH 5.0-6.0. These regulatory factors help to control the balance needed to prevent 
chaotic heparanase activity. 
 Heparanase is also regulated by extensive promoter methylation. In the human 
genome there are methylated cytosine bases followed by guanine bases known as “CpG 
islands.” CpG islands are associated with the 5’ region of most housekeeping and many 
tissue specific genes [162].  These methylated sites have a role in development, cell 
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differentiation, and the inactivation of X chromosomes and imprinted genes. Cytosine 
hypermethylation of the heparanase promoter is associated with inactivation of the 
heparanase gene. For example, two tumor cell lines (JAR (human choriocarcinoma) and C-6 
(rat glioma)) that were found to express low-level heparanase activity were found to have 
extensively methylated CpG islands. However, when these cells where treated with 
demethylating agents (5-azacytidine, 5-aza-2’-deoxycytidine) it resulted in the increase of 
heparanase mRNA, protein, and enzymatic activity [163]. This data indicated that the level of 
heparanase expression is inversely related to the methylation status of the heparanase 
promoter. Furthermore, hypomethylation of the CpG island in the heparanase promoter plays 
an important role in activating the heparanase gene in various tumor cell lines [163, 164].  
 Protein 53 or p53 is a tumor suppressor protein that plays a role in apoptosis, genomic 
stability, and inhibition of angiogenesis by regulating the cell cycle [165-167]. This 
“guardian of the genome” regulates a wide variety of cellular promoters and its mutation is 
found in 40-50% of human cancers [168]. Under normal physiological conditions, p53 
suppresses the heparanase gene. In a study by Baraz et al., they demonstrated that wild-type 
(WT) p53 binds to the heparanase promoter and inhibits its activity, whereas, the mutant p53 
variants failed to exert an inhibitory effect and activated heparanase promoter activity. 
Moreover, elimination or inhibition of p53 in several cell types resulted in a significant 
increase in heparanase gene expression and enzymatic activity. The regulation of heparanase 
by p53 provides a possible explanation for the frequent increase of heparanase levels 
observed in cancer after p53 mutation [169]. 
 Also, heparanase is regulated by cytokines tumor necrosis factor-alpha (TNF-α) and 
interferon-gamma (IFN-γ). TNF-α has the ability to induce apoptotic cell death, induce 
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inflammation, cause necrosis of some cancers and promote the growth of other types of 
tumor cells, etc [170].  IFN-γ is a cytokine that is critical for immunity against viral and 
intracellular bacterial infections and tumor control [171]. Both of these cytokines were found 
to induce heparanase mRNA expression 2-3 fold in cultured in endothelial cells and 
upregulated its enzymatic activity [172]. In addition, TNF-α and IFN-γ were associated with 
local heparanase induction upon elicitation of delayed-type hypersensitivity (DTH) reaction 
in the mouse ear. Interestingly, addition of anti-heparanase siRNA or a heparanase inhibitor 
halted the DTH inflammatory response [172].  
 Estrogen is a female sex hormone and one of the main driving forces in breast 
tumorigenesis. In a study by Elkin et al., four putative estrogen response elements were 
identified in the heparanase promoter region. Estrogen was shown to induce heparanase 
mRNA transcription in only estrogen receptor-positive breast cancer cells.  This result was 
confirmed when they discovered that the transcription of a luciferase reporter gene driven by 
the heparanase promoter was significantly increased in estrogen receptor-positive cells after 
estrogen treatment [173]. Furthermore, the estrogen effect on heparanase mRNA levels was 
abolished in the presence of pure anti-estrogen ICI 182780, indicating that the classic 
estrogen receptor pathway is involved in transcriptional activation of heparanase.  In vivo, 
exposure to estrogen augmented levels of heparanase protein in MCF-7 cells embedded in 
Matrigel plugs and correlated with increased plug vascularization. Collectively, this study 
shows how estrogen can induce heparanase overexpression and thus, promote breast 
carcinoma development and progression [173]. 
 Recently, heparanase has been shown to have a role in diabetes, thus it is makes sense 
that heparanase expression would be regulated by glucose. It has been shown that glomerular 
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heparanase expression is upregulated in rats and mice suffering from streptozotocin-induced 
diabetes [174]. Additionally, heparanase expression is upregulated in endothelial cells 
exposed to high levels of glucose [175]. Taken together, all of these data indicate that 
heparanase regulation must me tightly controlled to keep the delicate balance between 
normal physiological functions and disease.  
 
Section 6. Inhibition of heparanase 
 
Heparin and heparanase inhibition 
 As mention in the section entitled “Heparin in malignancies,” LMWH appears to 
prolong the survival of cancer patients. Four different types of LMWH increased the survival 
of patients with cancer and venous thromboembolism (VTE), but this favorable result could 
not be duplicated in non-cancer patients [176-178]. Despite VTE diagnosis, cause of death in 
these patients usually occurs from cancer [179]. It is thought that instead of preventing fatal 
emboli in cancer patients the LMWH may have direct/indirect effects on tumor growth and 
metastasis [180]. Vlodavsky et al. showed that LMWH is a potent inhibitor of heparanase 
[96]. While the mechanism by which heparin inhibits metastasis is not well understood, it has 
been suggest that LMWH indirectly inhibits metastasis by directly inhibiting heparanase 
enzymatic degradation. Inhibition of both heparanase activity and experimental metastasis 
was exerted by heparin species containing > 14 residues and having sulfate groups at both the 
N- and O-positions. Although O-desulfation abolished the inhibitory effect of heparin, O-
sulfated and N-substituted species of LMWH retained a high inhibitory potential [1]. 
However, there is no straightforward correlation between sulfation degree and heparanase 
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inhibiting activity of heparin derivatives. It was shown in a study by Naggi et al. and 
Vlodavsky et al. that 2-O-desulfated heparin derivatives were found to retain their 
heparanase inhibition activity. Moreover, there seemed to be a compensatory mechanism for 
this inhibition, where 2-O-sulfate nor 6-O-sulfate groups were found to be essential for 
heparanase inhibition, provided that at least one of these positions is extensively sulfated 
[181, 182].  
 
Heparanase inhibitors that function as substrate mimetics 
 Utilizing a systematic approach to discover the structure-activity relationship between 
modified heparin species and heparanase inhibition, Naggi et al discovered a pronounced 
gain of heparanase inhibition following glycol splitting of both the N-sulfated and the N-
acetylated forms of heparin [181]. Glycol-split derivatives of heparin are obtained by 
controlled periodate oxidation/borohydride reduction of natural or partially 2-O-desulfated 
heparins [181, 183]. Glycol splitting yielded heparin derivatives with increased flexibility, 
resulting in close interaction and more effective inhibition of heparanase enzyme [184]. 
Moreover, glycol splitting of C2-C3 bonds of non-sulfated uronic acid residues yield 
inhibitors that are not susceptible to limited cleavage by heparanase unlike heparin. Since the 
original glucuronic acid is modified it can no longer be recognized by heparanase and it does 
not stimulate the mitogenic activity of FGF-2 [181]. Last year, this novel heparanase 
inhibitor (glycol split heparin or SST0001) was shown to effectively inhibit myeloma growth 
in vivo, even when confronted with aggressively growing tumor within the human bone 
[185]. Glycol split heparin or SST0001 also diminishes heparanase induced shedding of 
syndecan-1, known to be a potent promoter of myeloma growth, indicating that SST0001 
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inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis 
[185]. It was further suggested that SST0001 will inhibit heparanase processing through 
cathepsin L inhibition [151] because inhibition of cathepsin L is notably augmented by 
heparin and HS [186]. However this level of inhibition might affect heparanase action in 
normal physiological processes, such as immune surveillance, tissue repair, and HS turnover. 
Additionally, SST0001 contains unnatural saccharide units and there is no clear pathway to 
degrade such a molecule, it is a concern if it is used as a long term anti-cancer therapeutic 
that it may accumulate within the body. 
As an analog of its natural HS substrate, heparin is commonly considered as a potent 
inhibitor of heparanase [187]. Heparin inhibition is a result of its high affinity for heparanase 
and its limited susceptibility to degradation by this enzyme [188]. Therefore, it is important 
to design inhibition mimetics that possess the qualities stated above but lack anti-coagulant 
activity.  One of these mimetics, known as PI-88 or sulfated phosphomannopentose, was 
found to have an IC50 comparable to heparin (IC50 = 1 µg/mL versus PI-88 IC50 = 2 µg/mL) 
[127, 189]. PI-88 exist as a highly sulfonated oligosaccharide mixture with an average
 
sulfation of three sulfates per mannose residue and a molecular
 
weight of 2100-2585 Da. PI-
88 exhibits anti-metastatic, anti-angiogenic, and anti-restenotic activities. PI-88’s inhibition 
of heparanase prevents the release of growth factors (FGF-1, bFGF, and VEGF) which in 
turn prevents the initiating events in angiogenesis. It also acts as an HS mimetic by 
complexing with the HS binding domain of certain growth factors thus preventing the 
formation of a HS-growth factor-receptor complex. It was demonstrated in mammary 
adenocarcinoma tumors in rats that continuous administration of PI-88 could inhibit growth, 
vascularity and lymph node metastasis [105]. Although PI-88 underwent Phase II clinical 
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trials for melanoma, myeloma, prostate cancer, hepatocellular cancer (HCC) , and lung 
carcinoma, the activity was modest at best [105, 190]. The clinical trials showed encouraging 
yet modest results for particularly difficult to treat malignancies of melanoma and HCC. 
Another issue faced by PI-88 was the development of immune-mediated thrombocytopenia, 
which is a serious problem that can lead to the development of associated thrombosis. 
Therefore, Progen Industries decided to halt further development of PI-88 [190]. In 2011, 
Progen announced that it was moving forward into Phase III clinical trials in liver cancer.  
Recently, Progen announced the start of Phase I clinical trials for a synthetic, fully sulfated 
HS mimetic, known as PG545, in patients with advanced non-hematologic, malignant solid 
tumors, excluding primary brain and spinal tumors 
(http://clinicaltrials.gov/ct2/show/NCT01252095). PG545 is a dual inhibitor that not only 
targets heparanase but inhibits tumor angiogenesis by sequestering angiogenic growth factors 
in the ECM, thus limiting subsequent binding to receptors [191]. Furthermore, PG545 
exhibits a pharmacokinetic profile that supports less frequent dosing compared with other HS 
mimetics [191]. However, no study results have been published for Phase I trials as of May 
2012. 
There are other polyanionic molecules that have been shown to inhibit heparanase, 
such as suramin and trachyspic acid (which display unknown mechanisms), calcium spirulan, 
maltohexaose sulfate, laminarin sulfate, and JG3. JG3 or oligomannurate sulfate is a 
semisynthetic sulfated oligosaccharide derived from marine oligomannurate blocks [87]. JG3 
inhibits heparanase by binding to its heparin binding domain. JG3 was first reported to 
significantly inhibit angiogenesis and tumor metastasis in animal models by targeting 
heparanase [192]. Zhang et al. later reported that JG3 also significantly inhibited in vivo 
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tumor growth through blocking NF-κB activation  [193]. JG3 was shown to decrease lung 
metastasis of B16-F10 melanoma cells in a dose dependent manner [192].  
 
Silencing of the heparanase gene 
 Edovitsky et al. sought to determine if heparanase gene silencing could suppress 
heparanase-related tumor metastasis and angiogenesis in an animal model. This study 
demonstrated that anti-heparanase ribozyme or siRNA down-regulated heparanase activity, 
tumor invasiveness, angiogenesis, and metastasis [153]. In a MDA-MB-425 cell xenograft 
model, tumors treated with anti-heparanase siRNA were less vascularized and less metastatic 
than control cells [194].  Since heparanase is overexpressed in brain metastatic breast cancer, 
Zhang et al. used miRanda and RNAhybrid to identify a candidate micro RNA that could 
directly target heparanase and suppress brain metastatic breast cancer. Ectopic miR-1258 was 
recently reported to suppress heparanase expression and activity, resulting in inhibition of 
experimental breast cancer brain metastasis [195]. miR-1258 was found to inversely correlate 
with heparanase expression, enzymatic activity, and cancer cell metastatic propensity. These 
findings were validated in paired clinical specimens of normal mammary gland versus 
invasive ductal carcinoma, and primary breast cancer versus brain metastatic breast cancer. 
Moreover, heparanase inhibition by treatment with miR-1258 resulted in changes of MMP-9 
and COX2 protein levels and the phosphorylation of Akt and EGFR. However, the cell 
invasiveness and numbers of brain metastasis could not be reversed in rescue experiments. 
This implied that other targets might also contribute to brain metastatic breast cancer other 
than heparanase alone [195].  
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Anti-heparanase peptides and antibodies 
 In a quest to develop anticancer heparanase inhibitors, Levy-Adam et al. sought to 
identify the protein domains responsible for HS and heparanase binding as a potential target 
for inhibition. Utilizing published consensus sequences that mediate the interaction between 
polypeptides and heparin, they identified three potential binding domains at Lys
158
-Asp
171
, 
Gln
270
-Lys
280
, and Lys
411
-Arg
432
 located within the 50 kDa subunit [196]. Of these potential 
binding sites, one (
158
KKFKNSTYRSSSVD
171
) was found to physically associate with 
heparin and HS more strongly and inhibits heparanase enzymatic activity in a dose dependent 
manner, presumably through competition with HS substrate. Furthermore, antibodies directed 
to this region (Lys
158
-Asp
171
) inhibited heparanase activity, and a deletion construct lacking 
this domain exhibited no enzymatic activity [196]. NMR titration experiments confirmed that 
residues Lys
158
-Asn
162
 as the amino acids that actually interacted and firmly bound with 
heparin. Ilan et al. introduced a cysteine residue at the peptide C-terminus and found that 
oxygenation and spontaneous dimerization of the peptide significantly improved its 
heparanase inhibiting activity [105]. Lastly, deletion of Gln
270
-Lys
280
 yielded an inactive 
enzyme that failed to interact with cell surface HS and high levels of heparanase accumulated 
in the culture medium of transfected HEK 293 cells [196]. Interestingly, Gingis-Velitski et al. 
produced a heparanase antibody that enhanced heparanase activity. This monoclonal anti-
heparanase antibody (6F8) enhanced the enzymatic activity of heparanase, facilitated in vitro 
tumor cell invasion, and improved wound healing in a mouse punch model [197].  
 The full length recombinant active enzyme has been used to immunize both rabbits 
and chickens for the generation of polyclonal antibodies. Addition of 100 µg/mL of anti-
heparanase anti-serum was shown to dramatically inhibit the invasion of human ovarian 
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cancer line OC-MZ-6 through matrigel by 95%, whereas addition of a control IgG antibody 
at a similar concentration had no effect [198]. However, the strategy of targeting heparanase 
via neutralizing antibodies towards a putative enzyme active site cleft or binding domain has 
been demonstrated in the treatment of restenosis and proteinuria but not cancer. 
 
Heparanase inhibition by small molecules 
 Small molecule inhibitors were reported that were represented by 1H-isoindole-5-
carboxylic acid and benzoxazol-5-yl-acetic acid. A second generation series of inhibitor 
namely the 1-[4-(1H-benzoimidazol-2yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-
ureas were developed by Imclone Systems Incorporated and evaluated for their inhibition 
potency and suitability for in vivo animal model studies [62, 189].  Among these, 1,3-bis-[4-
(1H-benzoimidazol-2-yl)-phenyl]-urea displayed excellent heparanase inhibitory activity 
(IC50 = 0.075 µM) in vitro and a good efficacy in a B16 experimental metastasis model [199]. 
Also there were other small molecule inhibitor but some were not deemed suitable for “proof 
of concept” evaluation in animal models (N-(4-{[4-(1H-benzoimidazol-2-yl)-arylamino]-
methyl}-phenyl)-benzamides) [200] and others have no published data on their efficacy in 
animal studies (Oxford Glycosciences (OGS) small molecule inhibitors) [62].  
 
Other inhibitory strategies 
 Uno et al. constructed an adenoviral vector carrying full length human heparanase 
cDNA in an antisense orientation (Ad-AS/ hep) to inhibit heparanase gene expression in 
human tumor cells [138]. Ad-AS/hep was able to inhibit increased heparanase expression in 
human tumor cell lines. Furthermore, Ad-AS/hep was able to inhibit both in vitro invasion of 
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the cells with heparanase expression and pleural dissemination of human tumor cells in a 
orthotopic model in vivo [138]. This strategy may be clinically more relevant for prevention 
of tumor cell spreading. 
 Cai et al. constructed a recombinant adenovirus vector with full length heparanase 
cDNA to produce specific antitumor immunity. The vector was transfected in dendritic cells 
from peripheral blood mononuclear cells of healthy HLA-A2 positive donors [201]. The 
modified dendritic cells activate heparanase specific cytotoxic T lymphocytes, resulting in 
potent, directed lysis of human gastric cancer KATO-III cells that were also heparanase 
positive and HLA-A2 matched. The heparanase cytotoxic T lymphocytes could not lyse cells 
that did not have both characteristics. For example, heparanase positive SGC-7901 cells were 
not lysed because they were not HLA-A2 matched [201] thus, displaying the specificity of 
this inhibition strategy. However, animal studies need to be performed to determine possible 
side effects associated with targeting heparanase as a universal immunotherapeutic for cancer 
treatment. 
  
Section 7. Structural recognition of heparanase 
 Although heparanase is a promising anti-cancer target there are currently no FDA 
approved anti-heparanase therapeutic agents for the treatment of metastasis or angiogenesis. 
Furthermore only one heparanase inhibitor (PI-88) has made it to Phase II clinical trials to 
date. This raises the question of: why has it been so challenging to discover heparanase 
modulators to target angiogenesis and metastasis? While several factors have contributed to 
hindering heparanase inhibitor discovery, these issues all stem from difficulties in the 
characterization of heparanase. In particular, the main issue that has hindered inhibitor design 
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significantly is the difficulty in defining the substrate specificity of heparanase. The substrate 
specificities of heparanase were confounded by the structural heterogeneity of HS 
polysaccharide substrates. Despite the fact that efforts have been made to define the 
specificity of heparanase, the two manuscripts in literature contain conflicting reports.  
  
Figure 10. Contradictory reports of heparanase specificity in literature. Panel A illustrates the findings 
from Pikas et al. study.  Based on their research, heparanase cleavage does not occur in the highly modified 
domain and whether the 2-O-sulfation was on the GlcUA or the IdoUA it was considered to be essential for 
heparanase recognition. Panel B illustrates the findings from Okada et al. study.  Based on their study, 
heparanase cleavage does occur in the highly modified domain and 2-O-sulfation was considered to be not 
essential for heparanase recognition, as indicated by the red “x” of the 2-O-sulfated uronic acid. 
 
It has been perceived that heparanase acts on specific sulfated saccharide sequences 
[111]. Pikas et al. [202] examined the specificity of heparanase utilizing an octasaccharide 
and a capsular polysaccharide of Escherichia coli K5 strain, as well as its chemically 
modified derivatives (Figure 10A). This study revealed that O-sulfo groups are important for 
heparanase recognition but not N-sulfation. Moreover, it was observed that if the 2-O-sulfate 
group on the IdoUA acid residue adjacent to the heparanase cleavage site is removed, the 
octasaccharide was no longer a substrate, indicating that 2-O-sulfation on the IdoUA or 
GlcUA was essential for recognition by heparanase. Furthermore, this study suggested that 
heparanase cleavage occurs in the lowly modified domain of HS. Several years later, Okada 
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et al. [203] further detailed the substrate specificity of heparanase using tetra- and 
hexasaccharides isolated heparin/HS with several types of sulfation on each fragment (Figure 
10B). The data from this report suggest the following: 1) the minimum heparanase 
recognition site is a trisaccharide; 2) heparanase cleaves the linkage of GlcUA and GlcNS 
that is 6-O-sulfated or 3, 6-O-disulfated; and 3) the 2-O-sulfo iduronic acid (IdoA2S) is 
nonessential for heparanase cleavage. Moreover, it stated that heparanase cleavage occurs in 
the highly modified region of HS. Despite their success, the results from these reports cannot 
provide a clear picture of which monosaccharide sequences are recognized by heparanase 
beyond the disaccharide/trisaccharide level. 
 
Section 8. Statement of problem 
 Heparanase cleaves HS, which is expressed in a variety of cells and tissues. The 
sulfation patterns and the position of the IdoUA residue of HS give rise to the selectivity that 
allows HS to bind to a variety of ligands and play a regulatory role in physiological processes 
such as embryogenesis [204] and pathological roles such as tumorigenesis [205]. The 
degradation by heparanase results in smaller HS fragments ranging in size from 10 to 20 
sugar units, and these fragments modulate the functions of growth factors and growth factor 
receptors [120]. Consequently, heparanase plays regulatory roles in several 
pathophysiological processes such as tissue remodeling, inflammation, angiogenesis, 
metastasis, and tumor progression [113-115]. The contribution of heparanase to tumor 
formation, invasion, and metastasis has been noted. The level of heparanase is up-regulated 
in a number of primary tumors such as head and neck, pancreatic carcinoma, hepatocellular 
carcinoma, and several cultured human tumor cell lines [124-128]. The overexpression of 
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heparanase has been correlated to an invasive phenotype in experimental animals [105]. 
Furthermore, heparanase has been linked to tumorigenesis in a wide array of cancers, such as 
breast, prostate, and colon [96, 129-138]. Thus, there is considerable interest to find the 
inhibitor of heparanase for anticancer drug development. 
  Therefore, defining the structural features of HS that alter heparanase cleavage may 
be essential for understanding how the binding of proteins can be modulated to regulate 
disease states. However, several challenges are associated with understanding the interaction 
between HS and heparanase. For example, many efforts have been made to define the 
structural recognition of heparanase but it is still difficult to decipher the precise contribution 
of each O-sulfation type to the susceptibility of heparanase, largely due to the fact that the 
choice of oligosaccharides contained multiple types of modifications. Furthermore, 
understanding the mechanism of HS depolymerization by heparanase has been limited by the 
lack of techniques to synthesize structurally defined oligosaccharides. To this end, whether 
heparanase recognizes single or multiple monosaccharide sequences and how this enzyme 
degrades HS-like substrates remains elusive.  To date, there have been no studies to explore 
the mode of action of HS depolymerization by heparanase. 
Our central hypothesis is that precise structural features within HS direct heparanase 
cleavage. In this thesis, I will define the substrate specificity of heparanase utilizing chemo-
enzymatically synthesized polysaccharide substrates.  Furthermore, I will utilize a systematic 
approach with structurally defined HS-like oligosaccharides and highly sensitive MS 
techniques to determine the features of HS that alter heparanase cleavage and the mode of 
HS degradation.  Thus, this thesis will provide the substrate specificity of heparanase needed 
for the design of an effective inhibitor. Moreover, it will reveal a unique control mechanism 
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for the action of heparanase and advance the understanding of the regulation of HS 
biosynthesis and the intimate relationship between HS and heparanase.   
 
  
Chapter II  
MATERIALS AND METHODS 
Section 1. Cloning, expression, and purification of heparanase  
Preparation of heparanase mammalian expression plasmid  
 The bacteria clone (clone 6250265) containing the full-length human heparanase was 
purchased from Open Biosystems (Huntsville, AL). Two primers, 5’-ATATTAGAATTC 
ATGCTGCTGCGCTCGAAGCCT-3’ and 5’-ATAAATTCTAGAGATGCAAGCAG 
CAACTTTGGC-3’, were synthesized, where the restriction sites of EcoRI and XbaI are 
underlined [26]. The PCR reaction was performed to amplify heparanase using the conditions 
as follows: 95 °C for 2 min, followed by 30 cycles of 95 °C for 30 s, 55 °C for 30 s, 68 °C 
for 2 min, and 68 °C for 10 min. The resulting PCR product was cloned into the pcDNA3.1-
A vector (Invitrogen) using EcoRI and XbaI sites to form a heparanase Myc-tagged protein. 
The plasmid (heparanase/pcDNA3.1) was confirmed by sequencing analysis (Genomic 
Analysis Core Facility, University of North Carolina). 
 
Expression of recombinant heparanase in CHO cells 
 Wild type Chinese hamster ovary (CHO) cells were transiently transfected with 
heparanase/pcDNA3.1 according to a standard protocol. Briefly, CHO cells were cultured in 
F-12 medium supplemented with 10% fetal bovine serum and maintained at 37 °C in a 5% 
CO2 humidified incubator. About 2 x 10
5
 cells were seeded per well (diameter, 3.5 cm) in a 
47 
 
6-well plate. Upon 90–95% confluence, transfection was performed with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. After 48 h, cells were harvested 
with a cell scraper and centrifuged (2,000 rpm for 8 min). The cells were lysed in 100 µl of 
lysis buffer (1% Triton X-100, 1.5 M sucrose, and 1 mM phenylmethylsulfonyl fluoride) on 
ice for 1 h. The lysate was centrifuged (at 12,000 rpm for 10 min at 4 °C), and the 
supernatant was collected. The expression level of heparanase in both cell lysate and medium 
was assessed by Western analysis using 10% SDS-PAGE blotted with mouse anti-Myc 
monoclonal antibody and anti-mouse horseradish peroxidase (Invitrogen). We only detected 
heparanase in cell extract. 
 
Preparation of heparanase yeast expression plasmid with His-tag 
 The 2 TEV constructs were synthesized by Genscript and the human heparanase/TEV 
constructs were inserted into pUC57. For construct 1 with only one TEV site between the 8 
kDa and 50 kDa subunits, two primers, 5’- ATGTTGCTTAGAAGTAAACCTGCC-3’ and 
5’- ATGGTGATGGTGATGGTGAGAGATACAGGCTGCGACTTTGGC-3’, were 
synthesized, to add 6-His tag to the C-terminus (Figure 11). The PCR reaction was performed 
to amplify heparanase using the conditions as follows: 95 °C for 2 min, followed by 30 
cycles of 95 °C for 30 s, 55 °C for 30 s, 68 °C for 2 min, and 68 °C for 10 min. The PCR 
product underwent DpnI digestion, DNA purification, and another round of PCR to add 
additional restriction sites for cloning into pcDNA3.1-A vector (Invitrogen). Two primers, 
5’- ATATTAGAATTCATGTTGCTTAGAAGTAAACCT-3’ and 5’- ATAAATTCT 
AGAATGGTGATGGTGATGGTGATGGTGATGGTGAGA-3’, were synthesized, to add 
an EcoRI site to the N-terminus and XbaI restriction site to the C-terminus with an additional 
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4-His tag (Figure 11). The PCR reaction was performed to amplify heparanase using the 
conditions stated above.  The resulting PCR product was cloned into the pcDNA3.1-A vector 
(Invitrogen) using EcoRI and XbaI sites to form a heparanase His-tagged protein. The 
plasmid (heparanase/pcDNA3.1) was confirmed by sequencing analysis (Genomic Analysis 
Core Facility, University of North Carolina). Two primers, 5’- ATATTAGGCGGCCGC 
ATGTTGCTTAGAAGT AAACCT-3’ and 5’- ATAAATGAATTCTTAATGGTGATGG 
TGATGGTGATGGTGATGGTGATG-3’, were synthesized, to add a NotI site to the N-
terminus and EcoRI restriction site to the C-terminus with an additional 2-His tag (Figure 
11). The PCR reaction was performed to amplify heparanase using the conditions stated 
above, DpnI digested, and purified. The resulting PCR product was cloned into the pKLAC2 
vector (Invitrogen) using NotI and EcoRI sites to form a heparanase 12 His-tagged protein. 
The plasmid (heparanase/pKLAC2) was confirmed by sequencing analysis (Genomic 
Analysis Core Facility, University of North Carolina). Construct 2 with 2 TEV sites was not 
cloned or expressed because of the result seen from Construct 1 which is discussed in 
“Expression and purification of heparanase from yeast expression system (K. Lactis cells).” 
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Figure 11. Optimized method for the preparation of yeast expression plasmid with His-tag. The TEV 
Construct underwent three sequential rounds of PCR to clone it into pKLAC2 and add a 12-His tag. The first 
round of PCR added a 6 His-tag. The second round of PCR lead to the addition of an EcoRI site at the N-
terminus and 4 additional His residues plus an XbaI site to the C-terminus. This allowed the PCR product to be 
cloned into pcDNA3.1A. The last round of PCR added a NotI site at the N-terminus and 2 additional His 
residues, a stop codon, and an EcoRI site to the C-terminus. This allowed the PCR product to be cloned into the 
pKLAC2 plasmid. 
 
 
 
Expression of recombinant heparanase in K. Lactis cells 
 K. lactis GG799 or K. lactis YCT598 were grown in YPG medium (1% yeast extract, 
2% Peptone and 2% galactose) for propagation, YCB medium (30 mM Tris-HCl, pH 7.0,  
11.7 g/L yeast carbon base, and 5 mM acetamide) for selection or YPCG medium (1%  
yeast extract, 2% Peptone, 2% casamino acids, and 2% galactose) for expression.   To 
construct the secreted form of recombinant proteins, the TEV construct was cloned into 
pKLAC2 downstream of the K. lactis α-mating factor domain (α-MF).  The constructs were 
linearized with Sac II, recovered using the QIAquick Gel Extraction Kit (Qiagen), and 
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transformed into K. lactis competent cells according to the manual of K. lactis Protein 
Expression Kit (New England Biolabs Inc.).   
Colonies that were grown on YCB agar medium were inoculated into 1 ml of YCB 
medium and incubating at 28 
o
C overnight with shaking at 250 rpm.  The overnight culture 
(50 µl) was expanded into 1 ml YPCGN medium, and induced by galactose for 48 h at 28 
oC.  The supernatant was assayed for heparanase activity.  Clones showing the highest 
activity were expanded to 1L cultures. After expansion, the supernatant was applied to 
Nickel column (G.E. Healthcare) and washed with buffer A (25 mM Tris, 500 mM NaCl, 30 
mM imidazole, pH7.5) at a flow rate of 3 ml/min. The protein was eluted with buffer B (25 
mM Tris, 500 mM NaCl, 250 mM imidazole, pH7.5). Fractions containing heparanase/TEV 
protein were pooled and stored for further analysis. 
 
Expression of TEV protease and purification 
Recombinant TEV protease was expressed in E. coli BL21 (DE3) strain (Stratagene). 
Typically, 1 L LuriaBertani (LB) broth with 50 μg/ml carbenicillin and 20 µg/ml of 
chlorophenicol was inoculated with 20-30 ml of an overnight culture and grown at 37°C until 
the OD600 reached 0.6–0.8. The culture was induced by addition of 200 μM isopropyl-β-
thiogalactopyranoside (IPTG) and grown at 18°C for 16-18 hrs. The cells are pelleted at 
7,000 rpm for 30 mins and then resuspended in Nickel column buffer A (25 mM Tris, 500 
mM NaCl, 30 mM imidazole, pH7.5). This solution is sonicated 2 x 30 secs (duty cycle 50, 
output control 7), and then spin at 10,000rpm for 30 mins. The supernatant was applied to 
Nickel column (G.E. Healthcare) and washed with buffer A (25 mM Tris, 500 mM NaCl, 30 
mM imidazole, pH7.5) at a flow rate of 3 ml/min. The protein was eluted with buffer B (25 
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mM Tris, 500 mM NaCl, 250 mM imidazole, pH7.5). Fraction containing TEV activity were 
pooled and stored at -80 
o
C with 15% glycerol until use. 
 
 
Expression of GS3 construct in Sf9 cells 
 
 The human single-chain GS3 construct for constitutively active heparanase was 
constructed by removing the linker region between Glu
109
 and Lys
158
 based on the report by 
Nardella et al. [161]. In this construct, the 8 kDa subunit and the 50 kDa subunit were 
covalently linked via 3 glycine-serine repeats with the insect cell nucleotide sequence 
GGCTCGGGATCGGGTTCT by replacing amino acid residues from Glu
109
-Lys
158
. This 
GS3 construct was synthesized by Genscript.  Heparanase GS3 construct was cloned into a 
pFastBac-Mel-HT vector with primers, 5’- ATATTAGCGAATTCACAAGACGTG 
GTCGACCTCGAT-3’ and 5’- ATAAATGCGGCCGCATTAGATACAAGCG 
GCGACCTTAGCGTTACGGAT-3’, where the restriction sites of EcoRI and Not I 
(underlined) [26]. Recombinant baculoviruses expressing heparanase GS3 [161] were 
generated using the Bac-to- Bac Baculovirus expression system (Invitrogen). Recombinant 
baculoviruses were used to infect Sf9 insect cells in suspension cultures (2.0 x 10
6
 cells/ml) 
grown in Sf-900 III SFM (Gibco) at 27.5 
o
C, 135 rpm. After 72 hrs of infection, the media 
was centrifuged at 1,000 rpm for 5 min to pellet the cells and the supernatant was collected. 
The supernatants were diluted 1:1 with a buffer containing 50 mM Tris-HCl and 150 mM 
NaCl, pH 7.5 and purified as outlined below. 
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Purification of recombinant GS3 Construct 
 
 The heparanase construct was expressed and purified using a similar method 
previously described in patent publication (U.S. Pat. No. 2007/0009989) [206]. Briefly, the 
diluted supernatant was applied to a Heparin HyperD column (Pall Life Sciences) and 
washed with buffer A (50 mM Tris-HCl and 150 mM NaCl, pH 7.5) at a flow rate of 2 
ml/min. The protein was eluted with buffer B (50 mM Tris-HCl and1.5M NaCl, pH 7.5). 
Fraction containing heparanase activity were pooled and stored at -80 
o
C with 15% glycerol 
until use. 
 
Section 2. Preparation of heparanase substrates  
Preparation of metabolically 
35
S-labeled HS from CHO cells 
 
Confluent cells (T75 flask) were incubated with 0.5 mCi/ml of sodium [
35
S]sulfate 
(MD Biomedicals) for 16 h at 37 °C in 5 ml of F-12 medium supplemented with 10% 
dialyzed fetal bovine serum (26). To the medium, 1 ml of solution containing 1 mg/ml 
Pronase (Sigma), 240 mM sodium acetate, pH 6.5, and 1.92 M NaCl was added and 
incubated at 37 °C overnight. The sample was then purified by a DEAE column that was 
equilibrated with a buffer containing 20 mM NaAcO, pH 5, 150 mM NaCl. The HS was then 
eluted with a buffer containing 20 mM NaAcO, pH 5, 1 M NaCl. The purified [
35
S]HS was 
dialyzed against 50mM ammonium bicarbonate using a 3,500 molecular weight cut-off 
membrane. The sample was treated with 0.1 M NaOH and 9mM sodium borohydride at 46 
°C for 16 h to cleave the linkage between HS and the core protein. The sample was finally 
treated with chondroitinase ABC (20 units/ml; Sigma) to remove chondroitin sulfate. The 
35
S-labeled HS was dried and ready for the subsequent analysis.  
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Preparation of 
35
S-labeled HS polysaccharide substrates 
 All synthetic polysaccharides started from heparosan, which was purified from the 
media of E. coli K5 using a DEAE column (30). 6-O-Sulfo heparosan (compound 2) was 
prepared by incubating heparosan and 6-OST-3. Briefly, 1 µg of heparosan, 0.3 mg/ml of 6-
OST-3 and 50 µM [
35
S]PAPS (1.3 x10
3
 cpm/pmol) were mixed in 100 µl of reaction buffer 
containing 50mM MES, 0.5% Triton X-100, pH 7.0. The reaction was incubated at 37 °C for 
16 h. The product was purified by a DEAE column. 
Alternatively, heparosan was converted to N-sulfo heparosan (compound 3) through 
chemical deacetylation and enzymatic N-sulfation. To prepare deacetylated heparosan, 
heparosan (20 mg/ml) was incubated in 0.1 M NaOH and 0.1 M NaBH4 and incubated at 50 
°C for 3 h. The reaction was neutralized with acetic acid and then dialyzed against 50 mM 
ammonium bicarbonate using a 3500 molecular weight cutoff membrane. The polysaccharide 
was then incubated in 2 M NaOH at 68 °C for 3 h and then neutralized by concentrated HCl 
(37%, w/w) followed by dialysis using a 3500 molecular weight cut-off membrane. The 
deacetylated heparosan (10 µg/ml) was N-sulfated using 0.075 mg/ml of NST and 50 µM 
[
35
S]PAPS (4.8 x 10
2
 cpm/pmol) in 100 µl of reaction buffer containing 50 mM MES, 0.5% 
Triton X-100, pH 7.0. The reaction was incubated at 37 °C for 16 h. The product was 
purified by a DEAE column. 
The N-sulfo heparosan (compound 3) was 6-O-sulfated using a mixture of 6-OST-1 
and 6-OST-3 to prepare N-sulfo 6-O-sulfo heparosan (compound 4). In brief, 1 µg of N-sulfo 
heparosan (compound 3) was incubated with 0.2 mg/ml of 6-OST-1, 0.3 mg/ml of 6-OST-3 
and 50 µM [
35
S]PAPS in 100 µl reaction buffer. After incubation at 37 °C for 16 h, the 
product was purified by DEAE chromatography. N-sulfo 3-O-sulfo heparosan (compound 5) 
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was prepared similar to compound 4 by replacing 6-OST-1 and 6-OST-3 with 0.1 mg/ml of 
3-OST-1. 
To prepare N-sulfo 2-O-sulfo heparosan (compound 6), N-sulfo heparosan 
(compound 3) was modified with 0.15 mg/ml of 2-OST and 50 µM [
35
S]PAPS in 100 µl of 
reaction buffer. N-sulfo 2-O-sulfo heparan (compound 7) was prepared using a mixture of 0.1 
mg/ml of C5-epimerase and 0.15 mg/ml of 2-OST with 50 µM [
35
S]PAPS in 100 µl of 
reaction buffer. The reactions were incubated at 37 °C for 16 h, and the products were 
purified by a DEAE column. 
 
Preparation of oligosaccharide substrates 
 All oligosaccharides were elongated from GlcUA-PNP, which was purchased from 
Sigma.  Penta-1 backbone with the structure GlcUA-GlcNTFA-GlcUA-GlcNTFA-GlcUA-
PNP, where GlcUA represents glucuronic acid and GlcNTFA represents N-
trifluoroacetylated glucosamine, was prepared using a previously described method [207]. 
Briefly, GlcUA-PNP were incubated with UDP-monosaccharide donor (UDP-GlcNAc, UDP-
GlcNTFA, or UDP-GlcUA) and bacterial glycosyltransferases (KfiA or pmHS2) in buffer 
containing 25 mM Tris-HCl (pH 7.2) and 10 mM MnCl2.  To ensure that >95% of UDP-
monosaccharide donor was converted to UDP, the reaction was incubated for 16 hrs at room 
temperature and analyzed by a polyamine-based HPLC column. After the addition of two 
monosaccharides, the reaction was purified by C18 column (Biotage), which was eluted with 
a linear gradient of 0 to 100% acetonitrile in H2O and 0.1% TFA over 60 min at a flow rate 
of 2 ml/min. The product was determined by exploiting the UV absorbance of the PNP-tag at 
310nm and the identity of the product was confirmed by ESI-MS. The reaction cycle was 
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repeated two times to prepare Penta-1 backbone. Further elongation of Penta-1 to Hepta-2 
and Nona-3 was achieved by additional cycles with the UDP-donors, KfiA, and pmHS2 
following the same procedure as above. Alternatively, by alternating the addition of GlcNAc-
GlcUA or GlcNTFA-GlcUA, we were able to synthesize Nona-4-8 by essentially the same 
protocol as above.  
The N-sulfation of the oligosaccharide backbones was completed by 
detrifluoroacetylation followed by N-sulfation with NST.  The oligosaccharide backbones 
were dried and resuspended (10 ml) in a solution containing CH3OH, H2O, and (C2H5)3N 
(v/v/v, 2:2:1). The reaction was incubated at 37 
o
C for 16 hrs until detrifluoroacetylation 
reached to completion. The detrifluoroacetylated substrates were dried, resuspended in H2O, 
and N-sulfated. In brief, N-sulfation was carried out N-sulfotransferase (67 µg/ml) and 0.45 
mM PAPS in a total volume of 20 ml to yield N-sulfated oligosaccharide substrates. 6-O-
sulfation is carried out using 20 µg/ml of 6-OST-1, 60 µg/ml of 6-OST-3, and 0.45 mM of 
PAPS in a buffer containing 50 mM MES. The 
35
S-labeled 6-O-sulfated products synthesized 
utilizing 0.1 mg/ml of 6-OST-1, 0.3 mg/ml of 6-OST-3, and 50 µM [
35
S]PAPS in a 100 µl 
reaction. The product purity and identity of the synthesized oligosaccharides (Penta-1, Hepta-
2, and Nona 3-8) was confirmed by high resolution DEAE-HPLC and ESI-MS, respectively. 
 
Section 3. Analytical procedures for heparanase substrates  
Synthetic polysaccharides 
To verify the structural composition of the enzymatically synthesized substrates, 
disaccharide analysis was performed using two distinct techniques: heparin lyase digestion 
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(Figure 12) and nitrous acid degradation (Figure 13). For heparin lyase digestion, sulfated 
heparosan (1–10 µg) was degraded with a mixture of heparin lyase I, II, and III (0.1 mg/ml 
each) in 300 µl of 50mM sodium phosphate, pH 7.0 (31). The digestion was incubated at 37 
°C overnight. The resultant disaccharides were isolated using a BioGel P-2 column followed 
by disaccharide analysis using reverse phase ion-pairing HPLC as described (31).  
 
 
Figure 12. Enzymatic digestion by lyases I, II, III. Lyase I, II,  and III have distinct substrate specificities but 
all cleave between the glucosamine and the uronic acid. Since the lyases cleave by β-elimination, it results in a 
unsaturated C4-C5 double bond therefore information can only be revealed about the glucosamine and not the 
uronic acid.  
To determine the presence of GlcA2S versus IdoA2S, nitrous acid degradation was 
performed by deaminative cleavage (pH 1.5) at the glycosidic linkage containing N-sulfo 
glucosamine units (32). After degradation, the disaccharides were isolated using a BioGel P-
2 column and analyzed using a C18 column (Grace Davison Discovery Sciences) under 
reverse phase ion-pairing HPLC conditions. 
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Figure 13. Nitrous acid degradation. There are two types of nitrous acid degradation: low pH and high pH 
nitrous acid degradation. Low nitrous acid degradation reacts with NS glucosamine while high nitrous interacts 
with a free amine. Nitrous acid degradation reveals information about the uronic acid because the glucosamine 
is reduced to a 2,5-anhydromannitol.  
 
High resolution DEAE-HPLC analysis 
To elucidate the cleavage dynamics of heparanase, recombinant heparanase was 
incubated with 
35
S-labeled Nona-3 and Nona-7 at 0, 5, 15, 25, 60, 120, 240, 480 mins.  The 
reaction was stopped by subsequent heating (100 
o
C, 5 min) and centrifugation (13,200 rpm 
for 5 min) to precipitate the insoluble material. The cleavage products were analyzed and 
separated on a NPR-DEAE column (4.6 mm ID x 7.5 cm, Tosoh Biosciences), which was 
eluted with a linear gradient 0 to 1 M NaCl in 20mM Tris-HCl (pH 7.5) over 60 min at a 
flow rate of 0.4 ml/min. 
Mass spectrometry analysis  
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MS analysis was performed on a Thermo LCQ-Deca. The oligosaccharides were 
dissolved in H2O and injected via direct infusion (30 µl/min) into the instrument. The 
experiments were performed utilizing a negative ionization mode with a spray voltage of 3 
KV and a capillary temperature of 160 
o
C. The MS data was acquired and processed using 
Xcalibur 1.3 software. 
Separation of oligosaccharide by gel permeation chromatography 
The heparanase-digested products were separated and purified by fractionation on a 
BioGel P2 (0.75 x 200 cm) (BioRad), which was equilibrated with a buffer containing 
0.1mM ammonium bicarbonate at a flow rate of 4 ml/hr.  The identity of the cleavage 
products were confirmed in the same way as described under “MS Spectrometry Analysis.” 
 
Section 4. Heparanase activity assays  
Assaying for heparanase enzymatic activity using polysaccharides 
 Enzymatic reactions were carried out in 50 mM MES, pH 6.0, containing 50,000 
counts per min of [
35
S]HS and 0.2 µg of heparanase. The reaction was incubated for 24 h at 
37 °C followed by subsequent heating (100 °C, 5 min) and centrifugation (13,200 rpm for 5 
min) to precipitate the insoluble material. The products were analyzed by gel permeation 
chromatography (GPC)-HPLC. Briefly, the reaction was injected into a TSK-gel 
G3000SWXL column (Tosoh Biosciences), which was equilibrated by a buffer containing 
20mM MOPS, 400mM NaCl, pH 7.0, at a flow rate of 1.0 ml/min. The performance of the 
GPC-HPLC was assessed using a set of protein standards, including blue dextran (2000 
kDa), β-amylase (200 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), 
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cytochrome c (12.4 kDa), and sodium azide (0.065 kDa). All these standards were purchased 
from Sigma. A shift of the 
35
S-labeled peak toward the lower molecular range indicated 
heparanase cleavage. 
 
Inhibition of the activity of heparanase 
The enzymatic reactions were assembled in a same way as described above in “Assaying for 
heparanase enzymatic activity” except with the addition of compound 2, 3, 7, or PI-88 (0.5–
50 µg/ml). Complete inhibition was indicated by the identical elution profiles of 
35
S-labeled 
substrate with or without heparanase cleavage on GPC-HPLC. 
 
Assay to probe heparanase purification efficiency 
 Ion exchange chromatography was utilized to measure the enzymatic activity between 
our constructs by monitoring the recoverable 
35
S-labeled substrate obtained after heparanase 
digestion. One hundred thousand counts per minute of 
35
S-labeled 10-mer (with GlcUA-
GlcNS6S repeats) was digested with increasing amounts of CHO enzyme 0, 5, 15, 30, 50 µl 
of enzyme to create a standard curve. The reactions contained 100,000cpm of 10-mer with 5 
µl of each heparanase enzyme. The standards and the reaction samples were incubated for 3 
hrs at 37 
o
C in 50 mM MES pH 6.0. The 0.2ml DEAE columns were prepared using DEAE-
Sephacel (Sigma). The columns were washed 4x with water, 4x with 250 mM NaCl, and 4x 
with UPAS (50mM NaoAc, 150 mM NaCl, 1M EDTA, and 3M UREA). The samples are 
mixed with 2 column volumes of UPAS and load on the column. Then the column is washed 
again with 4x UPAS and 3x 250 mM NaCl. The remaining bound 
35
S-labeled 10-mer is 
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eluted with 1M NaCl. This eluent is counted and the recoverable counts are compared to 
control and the std curve to determine the optimal enzyme.  
 
Assaying for heparanase enzymatic activity using oligosaccharides 
 Enzymatic reactions with 
35
S-labeled material were carried out as described in a 
previous manuscript [207]. The enzymatic reactions with unlabeled material were carried out 
in similar conditions with the following exceptions: 100 µg/ml of for each substrate (Nona 1-
8) and 3.75 µg/ml of heparanase. However, in the time course assay 100 µg/ml of substrate 
and 0.625 µg/ml of heparanase. The reaction was incubated for 0, 5, 15, 25, 60, 120, 240, and 
480 mins or 16 hrs at 37 
o
C followed by subsequent heating (100 
o
C, 5 min) and 
centrifugation (13,200 rpm for 5 min) to precipitate the insoluble material. The reaction was 
ready for subsequent analysis. 
 
 
 
 
 
 
 
  
Chapter III  
 
 
UNRAVELING THE SPECIFICITY OF HEPARANASE UTILIZING SYNTHETIC 
SUBSTRATES  
 
Section 1. Introduction  
 Heparanase is a promising anticancer target because of its involvement in cancer 
invasion and metastasis. Heparanase cleaves HS [1], a sulfated polysaccharide, and activates 
a series of HS-mediated cell proliferation and angiogenesis processes. Understanding the 
substrate specificity of heparanase will aid the discovery of heparanase inhibitors. Despite 
the many efforts made to elucidate the substrate recognition of heparanase, the results from 
these reports cannot provide a clear picture about the precise contribution of each O-sulfation 
type to the susceptibility of heparanase. Furthermore, the oligosaccharides used in these 
studies contained multiple types of modifications which may have contributed to the 
contradictory studies. Here, we sought to determine the specificity of heparanase using 
synthetic polysaccharide substrates. The substrates were prepared using purified HS 
biosynthetic enzymes, and each polysaccharide substrate has a unique sulfation pattern [208]. 
Using these substrates, we were able to dissect the structural moieties required for 
heparanase. Our data suggest that heparanase cleaves the linkage between a GlcUA unit and 
an N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo group. In addition, 
heparanase cleaves the linkage of a GlcUA unit and N-sulfo glucosamine unit with a 2-O-
sulfated GlcUA residue, not a 2-O-sulfated IdoUA residue, in proximity. We also discovered 
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that the polysaccharide with repeating disaccharide units of IdoUA2S-GlcNS inhibits the 
activity of heparanase. Our findings advance the understanding of the substrate specificity of 
heparanase and identify a lead compound for developing polysaccharide-based heparanase 
inhibitors. 
 
Section 2. Expression of heparanase in CHO cells 
 Recombinant heparanase was transiently expressed in CHO cells by transfecting  
the plasmid expressing Myc-tagged heparanase. The level of heparanase was determined by 
Western analysis (Fig. 14A). As expected, heparanase is synthesized as a 65-kDa protein 
(proheparanase), and a processed heparanase appeared at 50 kDa. It was reported that the N-
terminus is cleaved by cathepsin L to yield an active enzyme with a molecular mass of 50 
kDa [104, 111, 114]. The recombinant enzyme was incubated with 
35
S-labeled HS isolated 
from CHO cells to confirm the enzymatic activity. Indeed, the size of the degraded [
35
S]HS 
migrated toward smaller molecular mass range after heparanase treatment as determined by 
GPC-HPLC (Fig. 14B). This result is shown by the shift in the GPC chromatogram. The 
molecular mass of the cleavage products was measured by gel filtration chromatography 
using a TSK-gel G3000SWXL column. The molecular mass standards used were β-amylase 
(200 kDa), bovine serum albumin (66 kDa), carbonic anhydrous (29 kDa), and cytochrome c 
(12.4 kDa). The void volume (V0) and total column volume (Vt) were determined by 
resolving blue dextran (2000 kDa) and sodium azide (65 Da), respectively. Using protein 
molecular mass standards, we estimated the molecular mass of uncleaved HS was 69 kDa, 
whereas the molecular mass of heparanase-degraded HS was 10 kDa (Fig. 14C).  
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Figure 14. Preparation and characterization of recombinant heparanase. Plasmid expressing C-terminal 
Myc-tagged heparanase (Hep.) was transiently transfected into CHO cells. Heparanase was harvested from cell 
extracts. Panel A shows the presence of the 65-kDa unprocessed heparanase protein (top band) and the active 
50 kDa protein after proper intracellular processing (bottom band). Panel B indicates that the expressed 
recombinant heparanase protein possessed enzymatic activity. Panel C shows the size of the uncleaved material 
(69 kDa) versus the cleaved material (10 kDa) as indicated by arrows. cpm, counts per min. 
 
Further analysis of the size of heparanase-digested HS using BioGel P-10 suggested that 
>80% of the products are larger than decasaccharide (Fig. 15). We also observed a slight 
shift in the chromatogram of the 
35
S-labeled HS treated with pcDNA3.1-transfected cell 
extract (Fig. 14B). This observation is not unanticipated because CHO cells express 
endogenous levels of heparanase [209]. We also observed the extent of the cleavage of 
35
S-
labeled HS correlated with the amount of cell extracts in the reaction (data not shown).  
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We estimated that the level of heparanase from the overexpressed CHO cells was 60-fold 
higher than from the wild type CHO cells.  
 
 
 Figure 15. Size of the heparanase cleaved HS. 
35
S-labeled HS isolated from CHO cells was incubated with or 
without 0.2μg/ml of heparanase and analyzed by BioGel P-10. Panel A shows the profile of HS without 
heparanase pretreatment. Panel B shows the profiles of HS with the pretreatment of heparanase. Greater than 
80% of the product remained the size larger than decasaccharide. 
 
 
Section 3. Preparation of polysaccharide substrates with different sulfation patterns 
 We employed a library of polysaccharides to interrogate the substrate specificity of 
heparanase. The polysaccharides were prepared using different combinations of HS 
biosynthetic enzymes, allowing us to engineer the sulfation pattern in the polysaccharides. A 
total of seven polysaccharide constructs were prepared as shown in Fig. 16. The level of 
sulfations for each polysaccharide construct was estimated based on the number of [
35
S]sulfo 
groups transferred to the polysaccharide (Table 1). Disaccharide analysis of the 
polysaccharides was also conducted, confirming the presence of the desired sulfation 
types and levels (Fig 17). 
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Figure 16. Scheme for the synthesis of polysaccharide substrate. Heparosan, a capsular polysaccharide 
isolated from E. coli K5, was used as the starting material for substrate design. The synthesis was carried out 
using purified recombinant HS biosynthetic enzymes. The procedures for the enzymatic synthesis of 
polysaccharide substrates are described under “Experimental Procedures.” The polysaccharide substrates were 
purified using DEAE columns, and the desired structures were confirmed by disaccharide analysis. C5-epi, C5-
epimerase; NST, N-sulfotransferase.  
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Figure 17. RPIP- HPLC profiles of disaccharide analysis of the synthesized substrates. 
35
S-labeled 
substrates were degraded with heparin lyases I, II, III or nitrous acid at pH 1.5 and analyzed by RPIP-HPLC to 
determine their disaccharide composition. Panel A shows the compositional analysis of lyase degraded 
substrates 2 and 4. Panel B shows the compositional analysis of nitrous acid degraded substrates 5-7. 
 
Section 4. Contribution of each sulfation type on heparanase cleavage 
The contribution of sulfation on the glucosamine residue to the cleavage by heparanase 
 We examined the effect of N- and O-sulfation of glucosamine residue on the 
susceptibility to heparanase digestion. Two groups of substrates were prepared. Group I 
contains a single type of sulfation of the polysaccharides, including 6-O-sulfo heparosan (2) 
and N-sulfo heparosan (3). Group II contains two types of sulfation on the glucosamine units, 
including N-sulfo 6-O-sulfo heparosan (4) and N-sulfo 3-O-sulfo heparosan (5). To facilitate 
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the analysis, 
35
S-labels were introduced to the substrates. Because heparosan (1) was known 
to be resistant to the digestion [202], we did not test its susceptibility to heparanase digestion. 
 
Figure 18. GPC-HPLC profiles of polysaccharide substrates with or without heparanase digestion. Site-
specifically 
35
S-labeled polysaccharide substrates were incubated with 0.2 µg/ml of heparanase to determine the 
reactivity to the cleavage by the enzyme. The samples were then resolved by GPC-HPLC. Panels A-F shows 
the profiles of substrates 2,3,4,5,6 and 7 with or without heparanase treatment. cpm, counts per min. 
 
Both 6-O-sulfo heparosan and N-sulfo heparosan were exposed to heparanase, and the 
products were analyzed by GPC-HPLC. The elution profiles of the 
35
S-labeled substrates 
with or without heparanase from GPC-HPLC nearly overlapped, suggesting that neither of 
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the substrates was susceptible to the digestion of heparanase (Fig. 18, A and B). It has also 
been reported that N-sulfo heparosan is not a substrate for heparanase [202, 203]. Thus, our 
data confirmed the previous findings. Previous substrate studies also suggested that 
heparanase is unable to cleave the linkage of GlcAGlcNAc6S using the model 
oligosaccharide substrates [203]. Thus, our results are consistent with the reported conclusion 
derived from using oligosaccharide substrates. 
 We next tested substrates containing two types of sulfation, namely N- and O-
sulfation on glucosamine units (4 and 5). Both 4 and 5 differed in the position of the O-sulfo 
group on the glucosamine units. N-sulfo 6-O-sulfo heparosan (4) contained the O-sulfo group 
at the 6-OH position, whereas N-sulfo 3-O-sulfo heparosan (5) contained the O-sulfo group 
at the 3-OH position (Fig 16). The GPC-HPLC analysis of 4 and 5 (with or without 
heparanase treatment) revealed that the molecular mass of the polysaccharides were reduced, 
suggesting that both substrates were susceptible to digestion by heparanase (Fig. 18, C and 
D). Because substrate 4 was an excellent substrate for heparanase and can be prepared 
readily in a large quantity, we used it as a substrate for subsequent inhibition experiments as 
described below. It should be noted that substrate 5 contains the domain that is part of the 
antithrombin-binding site of the HS carrying anticoagulant activity [18]. It has been 
demonstrated that heparanase cleaves the oligosaccharide containing a linkage of -GlcA-
GlcNS3S6S- [202]; however, whether heparanase degrades the linkage of -GlcA-GlcNS3S- 
has not been reported. Taken together, our results demonstrate that both N- and O-sulfations 
(either 6-O-sulfation or 3-O-sulfation) are required for the cleavage by heparanase. 
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Effects of 2-O-sulfation on the susceptibility of heparanase digestion 
 The contribution of O-sulfation on the hexuronic acid unit to heparanase digestion 
was also investigated. Here, we prepared the substrate containing the -GlcA2S-GlcNS- (6) 
domain and the substrate containing the -IdoA2S-GlcNS- (7) domain. Substrate 6 was found 
to be cleaved by heparanase as demonstrated by the GPC analysis (Fig. 18E), suggesting that 
introduction of 2-O-sulfo groups to the GlcUA unit conferred susceptibility to digestion by 
heparanase. The results of the analysis of heparanase-treated substrate 7 revealed a starkly 
different situation. The 
35
S-labeled substrate 7 that carries the repeating unit of IdoA2S-
GlcNS is completely resistant to the heparanase digestion (Fig. 18F). 
 
 
Figure 19. GPC-HPLC profiles of substrate 7 (synthesized with 2-OST WT) with or without heparanase 
digestions. Substrate 7, containing IdoUA2S-GlcNS, was synthesized by wild type 2-OST. The substrate was 
incubated with 0.2 μg/ml of heparanase to determine the reactivity to the cleavage by the enzyme. The samples 
were then resolved by GPLC-HPLC. The profile shows substrate 7 with or without heparanase treatment. 
Partial cleavage was a result of heparanase recognition of the GlcUA2S units in the substrate. 
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It is very important to note that a partial cleavage of substrate 7 was observed if the 
substrate was prepared using wild type 2-OST (Fig 18). We conclude that this cleavage is 
due to the fact that a low level of -GlcA2S-GlcNS- is present in the substrate because wild 
type 2-OST sulfates both IdoUA and GlcUA (36). To overcome the contamination of 
GlcA2S in substrate 7, we utilized a 2-OST mutant (2-OST Y94I), which exclusively sulfates 
the IdoUA but not GlcUA [210]. 
 
Section 5. Evidence of substrate cleavage by heparanase 
Heparanase cleaves the linkage that contains nonsulfated glucuronic acid 
 We then proved that the linkage of –GlcUA-GlcNS (3S or 6S)- was indeed 
susceptible to the heparanase cleavage. To this end, we prepared two site-specific, 
35
S-
labeled substrates 4 and 5, where the 
35
S-label was located at the 6-OH position or the 3-OH 
position, respectively. The polysaccharides were digested with heparanase followed by 
nitrous acid degradation. The degraded products were analyzed for the presence of 
35
S-
labeled monosaccharide as illustrated in Figure 20. If heparanase cleaves the linkage of -
GlcUA-GlcNS3S- or GlcUA-GlcNS6S-, we should observe a 
35
S-labeled monosaccharide in 
the heparanase-treated substrates followed by nitrous acid degradation, whereas the 
monosaccharide should be absent in the substrate without heparanase treatment. As expected, 
35
S-labeled monosaccharide in heparanase-treated substrates 4 and 5 was observed as shown 
in Figure 20, whereas no monosaccharide can be detected in the control sample. Our data 
suggest that heparanase cleaves the linkage between GlcUA and GlcNS6S (or -3S). 
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Figure 20.  Determination of the heparanase cleavage sites within substrates 4 and 5. 
35
S-labeled substrates 
4 and 5 were degraded with nitrous acid with or without heparanase. The products were analyzed by BioGel-P2. 
Panel A shows the profile of substrate 4 with or without pretreatment of heparanase. Panel B shows the profiles 
of substrate 5 with or without pretreatment of heparanase. Panel C depicts the reactions involved in the nitrous 
acid degradation with or without pretreatment of heparanase. cpm, counts per min. 
 
 
Our next goal was to determine whether heparanase cleaves the linkage of -
GlcUA2S-GlcNS-, given the fact that substrate 6 is susceptible to heparanase cleavage. We 
prepared 2-O-
35
S sulfated substrate 6 and utilized the same method as described above with 
an intention to observe the 
35
S-labeled monosaccharide. However, we did not detect any 
35
S-
labeled monosaccharide, suggesting that heparanase does not cleave the linkage of                 
-GlcUA2S-GlcNS- directly (Fig 21). We then hypothesized that heparanase cleaves the 
linkage of GlcUA-GlcNS, whereas a GlcUA2S unit is located in proximity. To this end, N-
35
S sulfated substrate 6 was prepared. Substrate 6 was treated with heparanase followed by 
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the degradation with a mixture of heparin lyases, and the products were analyzed by BioGel 
P-2 (Fig. 22C). As shown in Fig. 22, a 
35
S-labeled monosaccharide ([
35
S]GlcNS) was 
observed in the heparanase-treated sample, while this monosaccharide was absent in the 
substrate without heparanase treatment. Taken together, our results confirmed that 
heparanase does not cleave the linkage of -GlcUA2S-GlcNS- but rather cleaves the linkage 
of –GlcUA-GlcNS- nearby. 
 
 
Fig 21. Determination of the heparanase cleavage sites within substrate 6 with 
35
S-labeled 2-O-sulfation. 
35
S-labeled substrate 6 was degraded with heparin lyases I, II, and III with or without heparanase pretreatment. 
The products were analyzed by BioGel P-2. It is worth noting that substrate 6 contains 
35
S-labeled 2-O-sulfation 
and unlabeled N-sulfation. Panel A shows the profile of substrate 6 without pretreatment of heparanase. Panel B 
shows the profiles of substrate 6 with pretreatment of heparanase. Panel C shows the reactions involved in 
heparin lyases digestion with or without pretreatment of heparanase. 
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Section 6. Polysaccharide 7 (-IdoUA2S-GlcNS- repeating unit) inhibits heparanase 
activity 
 As demonstrated above, polysaccharide 7, containing the repeating unit of -IdoUA2S-
GlcNS-, is not a substrate for heparanase, whereas substrate 6, containing -GlcUA2S-GlcNS-
, is a substrate. We hypothesized that polysaccharide 7 could serve as an inhibitor for 
heparanase. The reactions were then carried out in the presence of a range of concentrations 
0.5–50 µg/ml) of substrate 7. To demonstrate the structural selectivity, both substrates 3 and 
2 were also used.  
Figure 22.  Determination of the heparanase cleavage sites within substrate 6 with unlabeled 2-O-
sulfation. 
35
S-labeled substrate 6  was degraded with heparin lyases I, II, and III with or without pretreatment of 
heparanase. The products were analyzed by BioGel-P2. It is worth noting that substrate 6 contains 
35
S-labeled 
N-sulfation and unlabeled 2-O-sulfation. Panel A shows the profile of substrate 6 without pretreatment of 
heparanase. Panel B shows the profiles of substrate 6 with pretreatment of heparanase. Panel C shows the 
reactions involved in the heparin lyase digestion with or without pretreatment of heparanase. cpm, counts per 
min. 
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Substrate 3, with repeating disaccharide units of GlcA-GlcNAc, did not inhibit the enzyme 
activity even at a concentration of 50 µg/ml (Fig. 23A). Similarly, the same result was shown 
for substrate 2 with the repeating units of GlcUA-GlcNAc6S (data not shown). However, the 
activity of heparanase was clearly affected by polysaccharide 7 in a dose responsive manner 
(Fig. 23B). In fact, the addition of 50 µg/ml of polysaccharide 7 caused complete inhibition 
of the enzymatic activity. PI-88, a known inhibitor of heparanase, also exhibited the 
inhibition effect under these conditions (Fig. 23C). The inhibition potency of polysaccharide 
7 was comparable to PI-88. Collectively, these data concluded that the polysaccharide with 
the repeating disaccharide structure IdoA2S-GlcNS could serve as a heparanase inhibitor. 
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Figure 23. Inhibition of the activity of heparanase. Panel A shows the GPC-HPLC profiles of heparanase-
treated 
35
S-labeled substrate in the presence of different concentrations of N-sulfo heparosan (polysaccharide 3) 
as well as the untreated 
35
S-labeled substrate. Panel B shows the GPC-HPLC profiles of heparanase-treated 
35
S-
labeled substrate in the presence of different concentrations of N-sulfo 2-O-sulfo heparan (polysaccharide 7) as 
well as the untreated 
35
S-labeled substrate. Panel C shows the GPC-HPLC profiles of heparanase-treated 
35
S-
labeled substrate in the presence of different concentrations of PI-88 as well as the untreated 
35
S-labeled 
substrate. cpm, counts per min. 
 
Section 7. Conclusion 
In this chapter, we utilized synthesized polysaccharide substrates with systematically 
varied sulfations to determine the effects of N-sulfation, 6-O-sulfation, 2-O-sulfation, and 
epimerization on the susceptibility to heparanase cleavage. Synthetic polysaccharides offer 
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several advantages. First, the sulfation type is highly homogeneous due to the exclusive 
regioselectivity of the biosynthetic enzymes. Such sulfation selectivity was confirmed by 
disaccharide analysis. Second, the sulfation patterns in the synthetic polysaccharides are 
present in nearly all the HS isolated from natural sources. Thus, the synthetic polysaccharides 
represent the domain structures of HS isolated from natural sources. Third, the length of the 
synthetic polysaccharides is comparable to cellular HS. The results of our substrate 
specificity studies should represent the action of heparanase on cellular HS. In fact, the 
products of heparanase-cleaved HS are mainly larger than decasaccharides (Figure 15). Thus, 
studies with polysaccharide substrates should eliminate the potential artifacts using 
oligosaccharide substrates. In our study, we found that the polysaccharides containing -
GlcUA-GlcNS6S- and -GlcUA-GlcNS3S- are excellent substrates for heparanase. The effect 
of 6-O-sulfation is consistent with previous findings using oligosaccharide substrates [203]. 
We also found that the polysaccharide with a repeating unit of -GlcUA-GlcNAc6S- is not a 
substrate, consistent with the observation reported by Okada et al. [203] using an 
oligosaccharide substrate that contains the linkage of GlcUA-GlcNAc6S. The effect of 2-O-
sulfation on the hexuronic acid (GlcUA and IdoUA) is somewhat surprising. Our data 
suggested that the polysaccharide bearing the repeating unit of -GlcUA2S-GlcNS- is cleaved 
by heparanase. Although the structure of -GlcUA2S-GlcNS- has been suggested by Pikas et 
al. [202, 211] using a chemically sulfated N-sulfo heparosan, their conclusion could be 
complicated by the presence of other types of sulfation in the polysaccharide. Starkly 
different from -GlcUA2S-GlcNS- , the polysaccharide bearing IdoUA2S-GlcNS is not a 
substrate and serves as an inhibitor of heparanase. 
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Our results revealed the substrate specificity of heparanase, which is summarized in 
Figure 24. Heparanase cleaves the linkage of a non-sulfated glucuronic acid and glucosamine 
carrying N-sulfo or both N-sulfo and O-sulfo groups. Our model suggests that the enzyme 
recognizes certain sulfation patterns rather than specific sulfated monosaccharide sequences. 
Heparanase recognizes the N-sulfo group as well as the O-sulfo group at the glucosamine 
unit at +1 site. In the case that O-sulfation of glucosamine is absent, heparanase recognizes 
the GlcUA2S unit located at the +2 site for cleaving the substrate. Alternatively, heparanase 
possibly recognizes the GlcUA2S residue located at the -2 site. When replacing a GlcUA2S 
unit at the +2 (or -2) position with IdoUA2S, the site is no longer a cleavage site for 
heparanase. In addition, replacing the N-sulfo group with N-acetyl at the +1 position becomes 
resistant to heparanase degradation. It should be noted that whether the GlcUA2S located 
beyond +2 or -2 site affects the susceptibility to the heparanase cleavage remains to be 
determined. 
The active role of heparanase in tumor metastasis has attracted considerable interests 
in searching for an inhibitor of heparanase via different mechanisms of action [129]. A 
number of chemical entities are known to inhibit the activity of heparanase. Among them, 
sulfated oligosaccharides like PI-88 have reached phase III clinical trials. Heparin is also a 
potent inhibitor of heparanase [187, 212]. However, the anticoagulant activity of heparin 
could cause an undesired bleeding effect when used as an anticancer drug. Furthermore, 
heparin is capable of displacing the growth factors that are sequestered by the HS located in 
the ECM and consequently stimulates cell proliferation. Thus, there is a strong demand to 
maintain the activity for inhibiting heparanase while eliminating the anticoagulant or cell 
proliferation activities. Toward this goal, a glycol split heparin-like polysaccharide was 
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discovered by Naggi et al. [181]. Because the glycol split polysaccharide contains unnatural 
saccharide units and there is no clear pathway to degrade such molecule, it is a concern if it is 
accumulated in the body as a long term anticancer therapeutic. Here, we reported that a 
polysaccharide with the repeating unit of -IdoUA2S-GlcNS- can also serve as an inhibitor. It 
is known that the polysaccharide carrying the -IdoUA2S-GlcNS- repeating sequence has no 
anticoagulant activity or the activity in stimulating cell proliferation [213]. In fact, 
polysaccharide with -IdoUA2SGlcNS- serves as an inhibitor for fibroblast growth factor/HS-
mediated cell proliferation activity [214], a favorable property as an anticancer agent. Our 
next goal is to identify the minimum saccharide structure carrying the -IdoUA2S-GlcNS 
repeat for inhibiting the activity of heparanase. 
 
Figure 24. Proposed heparanase substrate recognition sites. Heparanase cleaves the linkage between a non-
sulfated GlcUA and GlcNS. If the +1 site is 3-O-sulfated or 6-O-sulfated, the enzyme cleaves. If the +1 site is 
not O-sulfated, the enzyme searches for the structure beyond the GlcNS at -1 or +1 site. It is possible to 
recognize the 2-O-sulfo group located at either the +2 site or at the -2 site. 
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The findings of this study revealed the recognition pattern of heparanase. The 
structural moiety recognized by heparanase includes a GlcUA unit and GlcNS unit carrying 
O-sulfations. The enzyme proved to be promiscuous in the aspect of the type and location of 
O-sulfation required for recognition. Furthermore, the polysaccharide containing GlcUA2S 
renders the susceptibility to heparanase cleavage. Our study also discovered that IdoUA2S-
GlcNS may serve as an inhibitor of heparanase enzymatic activity. The results should 
provide the substrate specificity of heparanase needed for the design of an effective inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter IV  
 
 
DIVERSE APPROACHES TO EXPRESSING RECOMBINANT HEPARANASE IN 
VARIOUS EXPRESSION SYSTEMS 
 
 
Section 1. Introduction 
 
 Heparanase, an endo-β-glucuronidase that cleaves HS, is synthesized as a 65 kDa 
protein that must undergo proteolytic cleavage for activation. This process of heparanase 
proteolytic activation is explained in detail in “Heparanase cellular processing.” Briefly, the 
process begins when pre-proheparanase (65 kDa) is first targeted to the ER and the signal 
peptide is then cleaved. Proheparanase is shuttled to the Golgi apparatus where heparanase is 
subsequently secreted via vesicles that bud from the Golgi. Once secreted, heparanase binds 
with cell membrane HSPGs and is rapidly endocytosed as a heparanase-HSPG complex that 
appears to accumulate in endocytic vesicles such as endosomes. Conversion of endosomes to 
lysosomes results in a change in the pH and as a result heparanase processing and activation 
to its mature form. Furthermore, heparanase must undergo proteolytic activation by cathepsin 
L in lysosomes to remove the 6 kDa linker and allow for proper interaction between the 50 
kDa and 8 kDa subunit to yield an active protein. However, it is this complex processing 
which renders the production of large amounts of pure active protein an extremely difficult 
task. 
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Our hypothesis is that controlling the proteolytic activation of heparanase will aid in 
the protein purity and production. We sought to express purified heparanase utilizing two 
approaches: 1) Use protein engineering to introduce artificial protease cleavage sites for 
heparanase activation or 2) Use protein engineering to produce a heparanase variant that 
lacks the need for proteolytic activation. Effective use of either approach would allow us to 
eliminate the need for in vivo proteolytic activation of heparanase and express large 
quantities of pure and active heparanase protein.  
  Three constructs were prepared using artificial linkers and expressed using a variety 
of expression systems, such as mammalian, yeast, and insect cells. Utilizing approach one, 
we generated two constructs with TEV protease cleavage sites instead of cathepsin L 
cleavage sites in order to increase proteolytic cleavage efficiency. Although one of these 
constructs was expressed in a yeast expression system, it had no enzymatic activity. An 
additional construct was created using approach two with three repeating glycine-serine units 
and lacked the need for proteolytic activation.  Our data suggest that this heparanase 
construct was effectively expressed in an insect cell expression system and contained 
enzymatic activity. In addition, heparanase was able to be purified from serum free media on 
a high density heparin column but not purified from serum containing medium or on a 
traditional heparin column. We also discovered that the heparanase may cleave the traditional 
heparin column at limited sites reducing the purification efficiency. Our findings advance the 
understanding of heparanase proteolytic activation and validate an efficient method to 
express and purify heparanase using an insect cell expression system. 
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Section 2. Issues with the expression of heparanase in mammalian expression system  
 Although we were able to express active-recombinant heparanase in a mammalian 
expression, this system is not ideal to express pure and large quantities of heparanase for 
three reasons. First, mammalian protein expression is known to be laborious and expensive 
[215]. Endogenous heparanase can be purified from various sources such as, the placenta, 
lymphoid organs (spleen), platelets, and macrophages; however, low heparanase expression 
levels lead to the necessity for laborious and expensive purification procedures. Toyoshima 
and Nakajima showed that purifying heparanase from platelets required 4 different 
chromatographic steps and 5 days [94]. In addition, the earliest purification studies showed 
loss of enzymatic activity after one or two chromatographic steps [216, 217].  Secondly, 
purification of endogenous heparanase leads to overall yields that are characteristically low. 
For example, a study by Fairbanks et al. described the purification of 22 µg of heparanase 
from platelets, with a yield of 6%. Similarly, Fuks and colleagues  (U.S. Pat. No. 5,362,641) 
report a 4,000 fold purification of heparanase from 1.4 kg of protein derived from Sk-Hep-1 
cells (human hepatoma cell line) only yielded 6.5 µg of purified heparanase protein or 1.9%. 
A 240,000-fold purification from the same cell line required over 500 liters of cell culture 
(U.S. Pat. No. 5,968,822). 
 Lastly, although heparanase is properly processed in these cells, no homogenously 
processed protein is obtained because the processing reaction is inefficient (Figure 14A). 
Therefore, you always get a mixture of unprocessed heparanase (Figure 14A ,dark top band) 
and processed heparanase (Figure 14A ,light bottom band). It would be difficult to obtain 
enough properly processed heparanase needed for purification. Additionally, the use of 
expression vectors driving the secretion of heparanase does not lead to the production of 
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recombinant heparanase in CHO cell conditioned media , which have to be further stimulated 
to secrete heparanase by the addition of calcium ionophore or PMA (U.S Patent No. 
2007/0009989). Collectively, this expression system is not ideal for large quantities of pure 
heparanase protein. 
 
Section 3. Expression of heparanase in bacteria expression system is not a realistic 
option 
 Although bacterial expression systems have a proven record of producing high levels 
of protein expression, it was not an option for heparanase expression. Heparanase is 
glycosylated at 6 asparagine residues (162,178,200, 217, 238, and 459) located in the 50 kDa 
subunit (Figure 25) and bacterial cells lack the ability to express post-translationally modified 
proteins. While heparanase glycosylations were shown to only affect secretion and ER-to-
Golgi transport [109], it has not been shown if the glycosylation sites could affect proper 
folding or stability. Furthermore, when heparanase was expressed in E. coli there was no 
detectable enzymatic activity (U.S Patent No. 2007/0009989). Therefore, we choose not to 
use this expression system.  
 
Figure 25. Known glycosylation sites of heparanase. The 65-kDa unprocessed heparanase protein is 
composed of a signal peptide, 8 kDa subunit, 6 kDa linker region, and a 50 kDa subunit. Heparanase is 
glycosylated at 6 asparagine residues (162,178,200, 217, 238, and 459) located in the 50 kDa. These 
glycosylations were shown to support transport kinetics and secretion. 
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Section 4. Expression and purification of heparanase from a yeast expression system (K. 
Lactis cells) 
 We sought to express large quantities of pure recombinant heparanase using protein 
engineering to introduce artificial protease cleavage sites for heparanase activation in K. 
Lactis cells. However, the difficult processing and proteolytic activation of heparanase made 
it a complex task. There were several issues to consider before we decided to alter the linker 
region of heparanase. Issue 1 was that large amounts of cathepsin L are needed to cleave 
heparanase in a cell free system [104, 218] (Figure 26, Issue 1). Therefore, we would have to 
express excessive amounts of cathepsin L as well as recombinant heparanase to obtain a low 
yield of active enzyme. Issue 2 was related to the post-translational modifications. It was 
shown that heparanase glycosylations are important to transport and secretion. Therefore it 
was critical to express heparanase in a cell system that was capable of post-translational 
modifications (Figure 26, Issue 2).  
 Issue 3 was associated with the cleavage of cathepsin L. It had been shown that 
cathepsin L cleaves the linker region at multiple sites [218], therefore the by-products from 
this cleavage reaction certainly reduces the recovery yield activity by resulting in a complex 
mixture. ( Figure 26, Issue 3). Hence, we could not use cathepsin L for proteolytic cleavage 
and needed to find a new protease. The last issue was associated with the purification. A tag 
was needed to increase purification efficiency (Figure 26, Issue 4). However, the incorrect 
location of the tag could result in an inactive protein [104]. 
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Figure 26. Issues with heparanase activation in a cell free system. Issue 1 shows that large amounts of 
cathepsin L are needed to fully cleave the 6 kDa linker to make active heparanase. Issue 2 shows heparanase 
contains 6 glycosylation sites so a system with post-translational modifications is needed. Issue 3 depicts how 
cathepsin L cleavage results in smaller fragments that could affect heparanase reactions. Issue 4 depicts that a 
tag is needed for later purification steps 
 
 To address the issues listed above, we introduced an artificial linker to regulate 
heparanase activation in a cell free system. We designed two constructs to express in K. 
Lactis cells. Construct 1 has a TEV cleavage site between the 8 kDa and 50 KDa subunits 
and construct 2 contains 2 TEV sites on either side of the 6 kDa linker (Figure 27). TEV 
protease is a highly site-specific cysteine protease that is found in the Tobacco Etch Virus. 
The optimal recognition site for this enzyme is the sequence Glu-Asn-Leu-Tyr-Phe-Gln-
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(Gly/Ser) and cleavage occurs between Gln and (Gly-Ser). The advantage of using this 
enzyme is its high specificity which prevented any undesired cleavage.  
 
 
Figure 27. Artificial TEV linker to regulate heparanase proteolytic activation. Two constructs were 
designed with artificial linkers. Construct 1 has a TEV cleavage site in place of the 6 kDa linker with cathepsin 
L cleavage sites. Construct 2 contains a TEV site on either side of the 6 kDa linker. The issues to physiological 
activation can be solved by altering the proteolytic enzyme to TEV, expression in a system with post-
translational modifications, C-terminus His-tag and complete cleavage of the linker prevents cleavage 
fragments.  
  
 
  
87 
 
Recombinant heparanase constructs 1 was transiently expressed in K. lactis cells by 
transfecting the plasmid expressing His-tagged heparanase. The level of heparanase was 
determined by Western analysis (Figure 28C) after nickel column purification (Figure 28A). 
As expected, this construct appeared at 53 kDa. To confirm the enzymatic activity, the 
recombinant enzyme was incubated first with 
35
S-labeled 6-O-sulfated heparosan, which was 
shown to be cleaved by the endogenous heparanase from our previous study [207].  
However, the size of the treated [
35
S]6-O-sulfated heparosan did not migrate toward smaller 
molecular mass as determined by GPC-HPLC (Figure 28B) suggesting that this heparanase 
enzyme possessed no enzymatic activity. Construct 2 could not be expressed in the yeast 
expression system. In conclusion, construct 1 had no enzymatic activity and  expression of 
construct 2 was unsuccessful. 
Fig 28. Expression of heparanase in a K. Lactis cells. Panel A shows the expression of construct 1 
heparanase after nickel column purification. Panel B shows that the construct possessed no enzymatic activity, 
which was indicated by a shift in the chromatogram on a GPC-HPLC. Panel C depicts the process needed to 
determine if heparanase construct 1 had activity. 
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This inactive protein is probably due to the glycosylation divergence between yeast 
and other eukaryotes. Glycosylation takes place in the Golgi and in animal cells further 
mannose residues are removed (only 2-6 Mannose residues) and additional sugars may be 
added, such as  GlcNAc, galactose, fucose, and sialic acid [219].  In contrast, yeast cells do 
not trim back their mannose residues because it lacks Golgi mannosidases present in higher 
eukaryotes. Instead mannose elongation takes place in a stepwise addition and can be up to 
75 residues long, with many branches [219]. Although there is no data to refute or confirm 
this idea, we hypothesize that the hypermannosylation that occurs in yeast expression 
systems may have affected the folding of heparanase construct 1. Thus, the misfolding of the 
protein could make the TEV cleavage site inaccessible resulting in an inactive protein.  
 
Section 5. Expression of heparanase in Sf9 cells   
 We sought to express recombinant heparanase using protein engineering to produce a 
heparanase variant that lacks the need for proteolytic activation; however this is a 
challenging feat. We used a protein structure prediction server and homology modeler to 
determine the secondary structure and folding of heparanase as well as how the natural linker 
may contribute to  heparanase activity or the lack there of. This is a model of heparanase 
based on the crystal structure of bacterial α-L-Arabinofuranosidase from family 51 (from c. 
thermocellum) (Figure 29). This enzyme hydrolyzes the α-1,3 linkage between a 
xylopyranose from the xylan main chain and a arabinofuranose substituent. Although their 
substrates are different, heparanase has been shown to have structural similarities with 
families 10, 39, and 51 [90].  
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Figure 29. Homology model of proheparanase and α-L-Arabinofuranosidase. This protein homology model 
of proheparanase is based on the crystal structure of Bacterial α-L-Arabinofuranosidase from family 51. 
Heparanase is composed of two domains: a TIM barrel catalytic domain and a β-sandwich C-terminal domain. 
The 6kDa linker in the catalytic domain is composed of  large bulky residues that seem to block the active site.  
 
WT heparanase exist as a dual domain protein with a TIM barrel fold catalytic domain and a 
B-sandwich C-terminal domain [106]. The linker located in the catalytic domain, consist of 
48 amino acids with a majority of them being charged, hydrophobic, and large bulky residues 
that seem to block the active site. Thus, we hypothesized that a shorter linker with neutral, 
hydrophilic, and/or flexible residues may result in a constitutively active enzyme that lacked 
the need for proteolytic cleavage. However, we were unsure what composition of amino 
acids would result in an active protein and there was no literature on constitutively active 
heparanase constructs. Since heparanase is a promising anti-cancer target, we assumed that 
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pharmaceutical companies may have studied this enzyme and designed an active enzyme. 
Therefore, we performed an extensive patent search and discovered that Merck Research 
Laboratories have designed a constitutively active heparanase enzyme known as GS3 
heparanase (U.S. Pat No. 2007/0009989).  
 
 
 
Figure 30. His-tag GS3 construct lack need for proteolytic activation. The GS3 construct is composed of 
three glycine-serine repeats. This construct does not need to be cleaved by a protease and contains a His-tag at 
the N-terminus. GS3 construct will be expressed in an insect cell system.  
 
 The GS3 construct contained 3 glycine-serine repeats which meant that no activating 
enzyme was required for activation (Figure 30). We expressed this N-terminal His-tagged 
protein in Sf9 cells with serum and serum free media. To confirm the enzymatic activity, the 
recombinant enzyme was incubated with 
35
S-labeled 6-O-sulfo heparosan synthesized 
chemo-enzymatically. We also observed a slight shift in the chromatogram indicating that 
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[
35
S]6-O-sulfated heparosan was degraded after heparanase treatment as determined by GPC-
HPLC (Figure 31). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. GPC profile of 
35
S-labeled 6-O-sulfo heparosan with or without GS3 heparanase cleavage. The 
GS3 construct was incubated with or without 
35
S-labeled 6-O-sulfo heparosan to determine if this construct 
possessed enzymatic activity. The sample was then resolved on GPC-HPLC. GS3 heparanase cleaved the 
35
S-
labeled polysaccharide substrate. cpm, counts per minute.  
 
 
Next, we utilized a protein structure prediction server and homology modeler to determine 
the secondary structure and folding of GS3 heparanase and how the GS3 linker may 
contribute to heparanase activity. This is a model of heparanase based on the crystal structure 
of bacterial α-L-Arabinofuranosidase from family 51 (from c. thermocellum) (Figure 32). As 
shown in Figure 32, the GS3 linker is significantly smaller and composed of flexible and 
neutral residues. This flexibility will allow for proper association of the 50 kDa and 8 kDa 
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subunits. Thus, the small size of the linker will allow substrates direct access to the active 
site. GS3 heparanase is ideal for any additional studies. 
 
Figure 32. Homology model of GS3 construct and α-L-Arabinofuranosidase. This protein homology model 
of GS3 heparanase  is based on the crystal structure of Bacterial α-L-Arabinofuranosidase from family 51. The 
GS3 linker in the catalytic domain is composed flexible and neutral residues that result in a constitutively active 
enzyme. 
 
Section 6. Assay to probe purified heparanase to determine purification efficiency 
 A large pitfall of assaying heparanase activity is that there is no assay that can 
quantitatively monitor the degradation of HS chains so that the purification efficiency can be 
assessed. Over the past 25 years a number of different assays have been developed using 
radioactive HS substrates [111]. These include monitoring the size of the 
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glycosaminoglycans by gel filtration chromatography or gel electrophoresis [216, 220-222], 
precipitation of long HS chains under conditions where short oligosaccharides are soluble 
[217, 223, 224], release of radioactivity from immobilized HS or heparin [225-227], or from 
35
S-HSPG incorporated into a basement membrane [228], and the inability of the heparanase 
product to be retained on  a HS-ligand column [229]. Recently, two additional assays were 
developed that used relatively low molecular weight substrates. The first assay used Arixtra 
as their substrate and heparanase activity was determined by measuring the change in 
anticoagulant activity following cleavage of the substrate using a standard chromogenic 
assay for anti-Xa activity [230]. The second assay uses a liquid chromatography-mass 
spectrometry method for detecting and quantifying the cleavage products using an internal 
heparin disaccharide as the standard [231]. Despite their efforts, there is no established assay 
to quantitatively measure heparanase enzymatic activity. 
 To determine the optimal recombinant enzyme, we designed a rapid assay which 
measures the enzymatic activity between our constructs. Our assay would measure the 
enzymatic activity of heparanase by monitoring the recoverable 
35
S-labeled substrate 
obtained after enzymatic action. Ideally, larger fragments or those not cleaved by heparanase 
would bind to the column while smaller fragments are those that had been cleaved by an 
efficient enzyme would not bind. The latter would result in lower counts per minute 
recovered. A standard curve was created by plotting the change in % of degraded substrate 
by increasing amounts of CHO enzyme (0, 5, 15, 30, and 50 µl).  This standard curve used to 
extrapolate how active each unknown sample was in comparison to the CHO enzyme 
standard. This extrapolated number was then multiplied by the volume of the material (from 
preload, flowthrough, wash and elute) and all divided by the amount of enzyme used in the 
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reaction. The final amount of units allowing us to distinguish between the activity of various 
recombinant enzymes after purification.  
 Initially, we tried to use DNA-spin columns but the result was inconsistent. Next, we 
tried DEAE-Sephacel columns and they provided use with a repeatable result. For our 
cleavable substrate, we first used 
35
S 6-O-sulfo heparosan because based on our previous 
experiments we knew this was efficiently cleaved by heparanase [207] and we knew that 6-
O-sulfated substrates bind very tightly to the DEAE column because we normally purify 
them using this protocol. However, the heterogeneous nature of the substrate made it difficult 
to determine how much cleavage was occurring. Therefore, we decided to make a 
homogenous 10-mer with GlcUA-GlcNS6S repeats as our substrate for the assay. This 
substrate provided us with an accurate and reproducible result. Collectively, utilizing 
35
S-
labeled 10-mer (GlcUA-GlcNS6S repeats) and DEAE columns we were able to distinguish 
between the recombinant enzymes. 
 This assay using homogeneous 10-mer and DEAE columns is ideal over previous 
methods for several reasons. First, most of the previous methods utilized HS, heparin 
preparations, or polysaccharides as their substrate. As seen from our result when we utilized 
polysaccharides or a heterogeneous substrate it is hard to accurately and consistently 
determine the % of cleavage. In their asssays, the HS/heparin fragments released by 
heparanase during catalysis could inhibit the enzyme. Furthermore, majority of HS is 
composed of unsulfated domains that are not digested by heparanase and may not bind to 
HS-ligand columns which could greatly affect the result. Our assay utilizes a homogenous 
10-mer with GlcUA-GlcNS6S repeats. The sulfations allow us to use ion exchange 
chromatography and the substrate only contains repeats of a structure that is known to be 
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degraded by heparanase thus, increasing the reliability and accuracy of our assay. Secondly, 
some of the assays did not directly measure heparanase degradation. For example, the assay 
that measures the release of HS chains from the basement membrane may be assaying an 
activator of heparanase present in the matrix rather than heparanase itself [111]. Another 
example is the assay that measures heparanase activity by measuring anti-factor Xa activity. 
Our assay directly measures the degraded products from heparanase catalysis. Lastly, some 
of the previous assays require a large amount of protein to be consumed per assay and the 
procedure is labor intensive. Our assay only uses 5 to 10 µl of enzyme per reaction. In 
addition, our assay is simple, inexpensive, and detection can be achieved in 30 mins. This 
resulting assay allowed us to semi-quantitatively determine our purification efficiency. 
 
Section 7. Purification of GS3 heparanase from serum containing media 
 Recombinant baculoviruses were generated and used to infect SF9 cells grown in 
serum containing medium (U.S. Pat. No. 2007/0009989). The GS3 heparanase construct 
contained an N-terminal 6-His-tag and was purified from the medium of infected insect cells 
on a nickel column by gravity.  However, the flowthrough contained the same amount of 
activity as the pre-load with little to no activity in the elute (data not shown). This indicated 
that the heparanase protein did not efficiently bind the nickel column so nickel column 
purification will not be a viable purification method. 
 Furthermore, the medium we prepared contained 10% serum which means that the 
protein concentration in the medium (6.2 g/L to 10 g/L) in comparison to the produced 
protein (few mg/L to 1g/L) is extremely high (http://www.athenaes.com/tech_brief_ 
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serum_free.php). This makes the separation of the recombinant heparanase from serum 
proteins a difficult process. This utilizing serum-free media may be a more ideal approach. 
 
Section 8. Purification of GS3 heparanase from serum-free media 
Following the inefficiency of the nickel column and the serum containing medium, 
we decided to produce recombinant baculoviruses to infect SF9 cells grown in serum-free 
medium. The GS3-linked heparanase was first purified by a traditional Heparin column. 
Since heparin is a potent inhibitor of heparanase and heparanase cleaves it at only a limited 
number of sites, we decided to go with this column because we knew heparanase had a high 
binding affinity to the heparin column [112]. We initially tried to purify the serum-free 
supernatant at room temperature using MES buffer at pH 6.0. However, these conditions are 
too close to the enzymatic reaction conditions (37 
o
C, pH 6.0). Thus, heparanase may have 
caused limited cleavage of the heparin that composes this column reducing it efficiency 
because we only saw 5-10% activity in the elutant.  
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Figure 33. FPLC-HPLC profile of GS3 heparanase. The supernatant was applied to a Heparin HyperD 
column and washed with buffer A (50 mM Tris-HCl and 150 mM NaCl, pH 7.5) at a flow rate of 2 ml/min. The 
protein was eluted with buffer B (50 mM Tris-HCl and1.5M NaCl, pH 7.5). Fraction containing heparanase 
activity were pooled and stored at -80 
o
C. The peak eluted in fractions 5 and 6. 
 
We also tried MOPS at pH 7.0 and Tris-HCl at pH 7.5 at room temperature. A higher 
pH reduces the enzymatic activity significantly because heparanase optimal activity is seen 
between pH 5.0-6.0 with barely any activity at physiological pH. To further reduce the 
activity, we performed the purification at 4 
o
C. Although we saw a slight increase in the % 
activity in elute (15-20%) using Tris-HCl at pH 7.5, 4 
o
C, it was not enough to be considered 
a success. Theoretically, we wanted to see greater than 50-60% activity in the elutant. We 
decided to use a 10 ml Hyper-D heparin column to purify heparanase supernatant on the 
FPLC (U.S. Patent No. 2007/0009989). The HyperD resin was ideal because it possessed a 
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higher protein binding capacity (25 mg/ml absorption capacity versus 2 mg/ml for traditional 
heparin column) and the heparin is tighter packed (5-10 mg/ml of immobilized heparin of 
sorbent versus 4mg/ml for the traditional column). Figure 33 shows the FPLC chromatogram 
of GS3 heparanase purified by HyperD column. The highest activity was seen in fractions 5 
and 6 which align with the chromatogram peak with some residual activity in fraction 7-10 
(Figure 34).  
 
Figure 34. Enzymatic activity of FPLC fractions. The DEAE-column assay was used to determine if the 
enzymatic activity aligned with the peak elution. Fractions 5 and 6 showed maximum activity which is where 
the chromatogram peak eluted. 
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Section 9. Conclusion 
 Several heparanase expression constructs were expressed using a variety of 
expression systems, such as mammalian, yeast, and insect cell expression system. We 
established an assay to semi-quantitatively probe the enzymatic activity of heparanase. 
Moreover, using this assay we were able to determine that the GS3 construct was the best. 
The GS3 construct with three repeating glycine-serine units, lacked the need for proteolytic 
activation.  Our data suggest that this heparanase construct was effectively expressed in an 
insect cell expression system and contained enzymatic activity. Heparanase was able to be 
purified from serum free media on a high density heparin column but not purified from 
serum containing medium or on a traditional heparin column. Our findings help to establish a 
quantitative method to assay enzyme activity and validate an efficient method to express and 
purify heparanase using an insect cell expression system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter V  
 
 
STRUCTURAL CUES WITHIN HS THAT DIRECT HEPARANASE CLEAVAGE 
 
 
Section 1. Introduction 
The underlying mechanism displayed by heparanase to preserve or cleave certain 
sequences is not well understood.  Although, many efforts have been made to elucidate the 
role of heparanase cleavage of HS within diseases (such as cancer, diabetes, and 
Alzheimer’s), less effort has been made to understand how structural cues within HS 
structure may direct cleavage or the sequence of events during HS depolymerization by 
heparanase. It has been proposed that heparanase acts by an endolytic mechanism [232].For 
heparanase, it has been difficult to unambiguously assign the mode of action because of the 
complexity of HS structure. Understanding the mechanism of HS depolymerization by 
heparanase has been limited by the heterogeneity of substrates and the lack of techniques to 
synthesize structurally defined oligosaccharides. In Liu et al. [233], we report advances in the 
methodology for synthesizing and analyzing oligosaccharides. These techniques, along with 
some additional methods discussed in this chapter, allow determination of specific substrate 
purity and structure (up to nonamers) as well as analysis of cleavage products during/after 
heparanase action. 
Therefore, we designed experiments to systematically assess if the structural features 
of HS direct heparanase cleavage and uncover the mode of action of heparanase. In this 
study, we employed a selective library of oligosaccharides coupled with ESI-MS 
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analysis to determine the substrate specificity of heparanase.  Although HS has complex 
saccharide sequences, the current study was only focused on the substrates containing the 
disaccharide repeating unit of –GlcUA-GlcNS6S- and –GlcUA-GlcNAc6S-.  The products of 
heparanase cleavage were used to determine heparanase preference for endolytic or exolytic 
cleavage at the reducing or nonreducing ends of substrates. Furthermore, time course studies 
were utilized to investigate whether heparanase cleaves nonprocessively or processively and 
the enzymes preference for certain substrates. Our data suggest that heparanase utilizes key 
structural features within HS to cleave endolytically starting with the first site of cleavage 
always occurring at the nonreducing end. The residue at the nonreducing end directs 
heparanase cleavage pattern. Moreover, heparanase depolymerizes HS utilizing a 
nonprocessive method. Our data reveals for the first time that heparanase is an editing 
enzyme that cleaves nonprocessively by utilizing specific residues within HS to yield 
particular fragments. This study advances our understanding of heparanase recognition of HS 
and reveals an additional level of HS regulation. 
  
Section 2. Preparation of structurally defined oligosaccharide substrates   
A library of oligosaccharides was synthesized to determine the specificity of heparanase. The 
library consisted of eight oligosaccharides carrying 6-O-sulfo groups (Figure 35). The 
synthesis was completed using a chemo-enzymatic approach, involving backbone elongation 
and sulfation steps. Elongation was completed using two bacterial glycosyl transferases, N-
acetylglucosaminyl transferase from E. coli K5 strain (KfiA) (Step a, Figure 35) and 
heparosan synthase 2 from Pasteurella multocida (pmHS2) (Step b, Figure 35). In this 
synthesis, a GlcUA derivative, GlcUA-PNP (PNP represents para-nitrophenol), was used as 
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a starting material because the PNP group has the absorbance at 310 nm and facilitated the 
detection during the analysis.   
 
Figure 35.  Scheme for the synthesis of oligosaccharide substrates.  The synthesis was initiated from 
GlcUA-PNP.  The starting monosaccharide was elongated by glycosyltransferases to the desired size.  The 
resultant oligosaccharides were then N-sulfated and 6-O-sulfated by N-sulfotransferase and 6-O-sulfotransferase 
1/6-O-sulfotransferase 3, respectively.  Total of eight oligosaccharides were synthesized.  The structural 
analysis of each oligosaccharide was conducted by ESI-MS (Supplementary Fig S1).  The purity was assessed 
by DEAE-HPLC (Supplementary Fig S2).  Abbreviations: KfiA, N-acetyl glucosaminyl transferase of E. coli 
K5 strain; pmHS2, heparosan synthase-2 of Pasteurella multocida; NST, N-sulfotransferase; PAPS, 3’-
phosphoadenosine 5’-phosphosulfate; 6OST, 6-O-sulfotransferases.   
 
The backbone oligosaccharides contained strategically placed GlcNTFA (N-trifluroacetyl 
glucosamine) residues, which were converted to GlcNS residues readily in a later step (Step c 
and d, Figure 35) [207] This design allowed us to control the positions of GlcNS residue in 
the oligosaccharides (Step c and d, Figure 35).  At the 6-O-sulfation step (step e, Figure 35), 
these oligosaccharides were fully 6-O-sulfated by 6-OST-1 and 3.  The structures of the 
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substrates were confirmed by electrospray ionization mass spectrometry (ESI-MS) (Figure 36 
and Table 2). The 6-O-[
35
S]sulfo labeled substrates showed a single symmetric peak in a high 
resolution DEAE-HPLC trace (Figure 37 and Table 2), suggesting that the purity of 
substrates was high.  It is important to note that such structurally diversified 6-O-sulfated 
nonasaccharide library has not been reported previously. 
 
Figure 36. ESI-MS profiles from structural analysis of the synthesized substrates. Chemoenzymatic 
synthesized substrates were dissolved in H2O and injected via direct infusion to ESI-MS. Utilizing a negative 
ionization mode, the substrates were analyzed to determine their structural composition. The top profiles (left to 
right) show the structural analysis of Penta-1, Hepta-2, Nona-3, and Nona-4. The bottom profiles (left to right) 
show the structural analysis of Nona-5, Nona-6, Nona-7, and Nona-8. 
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Figure 37. DEAE-HPLC profiles from structural analysis of the synthesized substrates. 
35
S-labeled 
substrates were analyzed by DEAE-HPLC to determine their structural purity. The left profiles (top to bottom) 
show the purity of Penta-1, Hepta-2, Nona-3, and Nona-4. The right profiles (top to bottom) show the structural 
analysis of Nona-5, Nona-6, Nona-7, and Nona-8. All of the 6-O-[
35
S]sulfo labeled substrates showed a single 
symmetric peak in a high resolution DEAE-HPLC trace, indicating high substrate purity. 
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Section 3. Minimum size for a heparanase substrate  
We sought to determine if the heparanase cleavage is dependent on the size of the substrate. 
To this end, we employed three oligosaccharides (Penta-1, Hepta-2 and Nona-3) that 
contained different numbers of GlcUA-GlcNS6S repeating unit: Penta-1, Hepta-2 and Nona-
3 have two, three and four repeats of the unit, respectively. Assuming that the susceptibility 
of the glycosidic bond for cleavage is influenced by flanking residues, we employed only 
GlcUA-GlcNS6S repeats to prevent any biased that could be introduced by structural 
variations in the substrates.  Subjecting 
35
S-labeled Nona-3 to heparanase digestion yielded 
three products as measured by gel-permeation chromatography (BioGel P-2), suggesting that 
two glycosidic bonds were susceptible to the digestion (Figure 38A).  Structural analysis of 
heparanase-digested Nona-3 was carried out by ESI-MS.  In this experiment, unlabeled 
Nona-3 was first digested with heparanase, and then the products were resolved by a BioGel 
P-2 column.  The fractions from the BioGel P-2 column were subjected to ESI-MS analysis.  
An oligosaccharide with the molecular mass of 1012.8 ± 0.2 Da was identified in Fraction 
42, which is very close to the calculated molecular mass of 1012.8 Da for a tetrasaccharide 
with a structure of GlcNS6S- GlcUA-GlcNS6S-GlcUA (Tetra-17) (Figure 38B and Table 3).  
The data suggest that this tetrasaccharide was from the middle segment (Residue 4-7) of 
Nona-3 (Figure 38 and Table 2).  Using a similar method, a trisaccharide with a structure of 
GlcUA-GlcNS6S-GlcUA (Tri-12) and a PNP-tagged disaccharide with a structure of 
GlcNS6S-GlcUA-PNP (Di (PNP)-9) were identified (Figure 38B and Table 3).  These data 
allowed us to determine the heparanase cleavage of Nona-3 in Figure 38C. 
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Figure 38. Analysis of heparanase-digested Nona-3.  Panel A shows the BioGel P-2 elution profiles of 
35
S-
labeled Nona-3 without digestion (top) and with heparanase digestion (bottom).  Panel B shows the ESI-MS 
spectra of heparanase-digested Nona-3 of fractions eluted from P-2 column.  The left panel shows the spectrum 
of Tri-12 from fractions 51 to 57.  The middle panel shows the spectrum of Tetra-17 from fractions 43 to 49.  
The right panel shows the spectrum of Di (PNP)-9 from fractions 71 to 75.  Panel C shows the chemical 
reaction involved in the digestion of Nona-3 with heparanase. 
 
Digestion of 
35
S-labeled Hepta-2 with heparanase yielded two 
35
S-labeled products, 
suggesting that the substrate contained a single cleavage site (Table 2 and Figure 39A). 
Unlike Nona-3, about 15% of the Hepta-2 remained undigested, suggesting that the 
susceptibility of the substrate to the digestion of heparanase is size-dependent.  The structures 
of those two products were identified to be a trisaccharide (Tri-12) with the molecular mass 
of 691.0 ± 0.2, close to the calculated molecular mass of GlcA-GlcNS6S-GlcA (691.6); and a 
tetrasaccharide (Tetra (PNP)-14) with the molecular mass of 1134.0 ± 0.4, close to the 
calculated molecular mass of GlcNS6S-GlcA-GlcNS6S-GlcA-PNP (1133.9) Figure 39B, 
39C and Table 2). 
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Figure 39. Analysis of heparanase-digested Hepta-2.  Panel A shows the BioGel P-2 elution profiles of 
35
S-
labeled Hepta-2 without digestion (left) and with heparanase digestion (right).  Panel B shows the ESI-MS 
spectra of heparanase-digested Hepta-2 of fractions eluted from P-2 column.  The left panel shows the spectrum 
of Tri-12 from fractions 53 to 59. The right panel shows the spectrum of Tetra (PNP)-14 from fractions 71 to 
81.  Panel C shows the structures of the cleavage products yielded from heparanase digestion.  
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Interestingly, subjecting Penta-1 to heparanase digestion resulted in partial digestion as 71% 
of starting material remained (Figure 40), further strengthening the conclusion that the 
susceptibility to heparanase cleavage is dependent on the size of the substrate.  
The results from the structural analysis of the cleavage products suggest that 
heparanase only cleaves the internal glycosidic linkages.  For example, when Nona-3 was 
used as a substrate, heparanase did not cleave the bond between Residue 1 and 2, 
representing an exo-glycosidic bond.  A similar phenomenon was observed for shorter 
substrates: Hepta-2 and Penta-1.  Our result is consistent with the conclusion that heparanase 
is an endolytic hydrolase [174, 203].  It is also important to note all examined 
oligosaccharides consist of repeating disaccharide unit of -GlcUA-GlcNS6S-, which unit is 
known to susceptible to heparanase digestion [207].  For an exo-glycosidic bond, the 4-OH 
position of the GlcUA residue in the –GlcA-GlcNS6S- repeating unit is occupied by a proton 
(-H) thus, heparanase cleavage would yield a monosaccharide (GlcUA).  For an endo-
glycosidic bond, the 4-OH position of the GlcUA is occupied by a GlcNS6S residue 
therefore; heparanase cleavage would yield a disaccharide with the structure GlcNS6S-
GlcUA.  Thus, our results provide direct evidence that heparanase can distinguish the 
functional group that is attached to the 4-OH position, exclusively displaying endolytic 
glucuronidase activity.   
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Figure 40. Analysis of heparanase-digested Penta-1.  Panel A displays the BioGel P-2 elution profiles of 
35
S-
labeled Penta-1 without heparanase digestion (top) and with digestion (bottom).  Panel B shows the ESI-MS 
spectra of Penta-1 of fractions eluted from P-2 column after heparanase digestion.  The top panel shows the 
spectrum of Penta-1 and Tri-12 from fractions 31 to 41. The bottom panel shows the spectrum of Di (PNP)-9 
from fractions 47 to 51.  Panel C shows the chemical reaction involved in the digestion of Penta-1 with 
heparanase. 
 
Section 4. The role of NS6S/NAc6S in directing heparanase cleavages  
GlcUA-GlcNS6S structures adjacent to GlcUA-GlcNAc6S are present throughout HS 
in mixed domains.   Although heparanase is known to cleave the linkage of –GlcUA-
GlcNS6S-, the effect of a nearby disaccharide unit of –GlcUA-GlcNAc6S- on the action of 
heparanase has not been investigated.  Here, we prepared a series of nonasaccharide 
substrates that contained the mixing disaccharide units of GlcUA-GlcNAc6S and GlcUA-
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GlcNS6S.  The GlcUA-GlcNAc6S can be located at the nonreducing (Nona-4 and Nona-5), 
reducing end (Nona-6), both ends (Nona-7), and alternating with GlcUA-GlcNS6S units 
(Nona-8).  These substrates provided us the opportunity to systematically examine the 
contribution of the GlcNAc6S motif to the selection of cleavage sites by heparanase.  The 
35
S-labeled and unlabeled substrates were treated with heparanase and analyzed by BioGel 
P2 and ESI-MS (Table 2 and Figures 41-45).  All these substrates, with the exception of 
Nona-8, were completed digested by heparanase. 
 
Figure 41. Analysis of heparanase-digested Nona-4.  Panel A shows the BioGel P-2 elution profiles of 
35
S-
labeled Nona-4 without digestion (top) and with heparanase digestion (bottom).  Panel B shows the ESI-MS 
spectra of heparanase-digested Nona-4 of fractions eluted from P-2 column.  The left panel shows the spectrum 
of Tri-13 from fractions 41 to 45. The right panel shows the spectrum of Di-10 and Tetra (PNP)-14 from 
fractions 63 to 71 and 45 to 53, respectively.  Panel C shows the chemical reaction involved in the digestion of 
Nona-4 with heparanase. 
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Figure 42. Analysis of heparanase-digested Nona-5.  Panel A shows the BioGel P-2 elution profiles of 
35
S-
labeled Nona-5 without digestion (top) and with heparanase digestion (bottom).  Panel B shows the ESI-MS 
spectra of heparanase-digested Nona-5 of fractions eluted from P-2 column.  The left panel shows the spectrum 
of Tri-13 and Tetra (PNP)-14 from fractions 39 to 45 and 45-53, respectively. The right panel shows the 
spectrum of Di-11 from fractions 59 to 67.  Panel C shows the chemical reaction involved in the digestion of 
Nona-5 with heparanase. 
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Figure 43. Analysis of heparanase-digested Nona-6.  Panel A shows the BioGel P-2 elution profiles of 
35
S-
labeled Nona-6 without digestion (top) and with heparanase digestion (bottom).  Panel B shows the ESI-MS 
spectra of heparanase-digested Nona-6 of fractions eluted from P-2 column.  The left panel shows the spectrum 
of Tri-12 from fractions 50 to 57.  The middle panel shows the spectrum of Tetra-17 from fractions 43 to 48. 
The right panel shows the spectrum of Di (PNP)-9a from fractions 62 to 69.  Panel C shows the chemical 
reaction involved in the digestion of Nona-6 with heparanase. 
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Figure 44. Analysis of heparanase-digested Nona-7.  Panel A shows the BioGel P-2 elution profiles of 
35
S-
labeled Nona-7 without digestion (top) and with heparanase digestion (bottom).  Panel B shows the ESI-MS 
spectra of heparanase-digested Nona-7 of fractions eluted from P-2 column.  The left panel shows the spectrum 
of Tri-13 from fractions 39 to 43.  The middle panel shows the spectrum of Di-11 from fractions 57 to 63. The 
right panel shows the spectrum of Tetra (PNP)-15 from fractions 45 to 50.  Panel C shows the chemical reaction 
involved in the digestion of Nona-7 with heparanase. 
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Figure 45. Analysis of heparanase-digested Nona-8.  Panel A shows the BioGel P-2 elution profiles of 
35
S-
labeled Nona-8 without digestion (top) and with heparanase digestion (bottom).  Panel B shows the ESI-MS 
spectra of heparanase-digested Nona-8 of fractions eluted from P-2 column.  The left panel shows the spectrum 
of Tri-13 and Tetra (PNP)-16 from fractions 45 to 51 and 51 to 56, respectively. The right panel shows the 
spectrum of Di-11 from fractions 57 to 61.  Panel C shows the chemical reaction involved in the digestion of 
Nona-8 with heparanase. 
 
Carefully examining the structures of the digestion products from six nonasaccharide 
substrates revealed that the cleavage sites by heparanase depend on the substrate saccharide 
sequences (Figure 46).  Two groups were observed: consecutive cleavage and gapped 
cleavage.  In the consecutive cleavage group, heparanase cleaved the glycosidic bond 
between Residue 3 and 4 as well as the one between Residue 5 and 6, whereas the bond 
between Residue 7 and 8 remained intact, resulting in a trisaccharide, a disaccharide and 
PNP-tagged tetrasaccharide product.  Four nonasaccharide substrates, including Nona-4, 
Nona-5, Nona-7 and Nona-8, displayed the consecutive cleavage pattern (Figure 46A and 
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Table 2).  In the gapped cleavage group, heparanase cleaved the glycosidic bond between 
Residue 3 and 4, and the one between Residue 7 and 8, while the linkage of Residue 5 and 6 
was untouched, resulting in a trisaccharide, a tetrasaccharide and a PNP-tagged disaccharide.  
Two nonasaccharides, Nona-3 and Nona-6, displayed the gapped cleavage pattern (Figure 
45B and Table 2).  The notable structural differences among these nonasaccharides are 
located at the nonreducing end.   
 
Figure 46.  Schematic representation of heparanase cleavage toward different nonasaccharide substrates.  
Panel A shows the cleavage pattern of consecutive cleavage.  When a GlcNAc6S residue is present at the 
Residue 2, heparanase displays consecutive cleavage pattern, namely cleaving the linkages between Residue 3 
and 4 as well as Residue 5 and 6.  Panel B shows the cleavage pattern of gapped cleavage.  When a GlcNS6S is 
present at Residue 2, heparanase displays gapped cleavage pattern, namely cleaving the linkages between 
Residue 3 and 4 as well as Residue 7 and 8, while skipping the bond between Residue 5 and 6.   
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In Nona-4, -5, -7 and -8 (consecutive cleavage group), a GlcNAc6S is present at Residue 2; 
while this residue is replaced by a GlcNS6S residue in Nona-3 and -6 (gapped cleavage 
group) (Figure 46B and Table 2).  Our data suggest that heparanase is capable of recognizing 
a GlcNS6S and GlcNAc6S residue on the nonreducing side, which determines the cleavage 
susceptibility of the remaining sites. 
 
Section 5. Site preference by heparanase cleavage  
To establish whether heparanase utilizes a processive or nonprocessive mode of 
action, we performed a time course of the enzyme catalyzed reaction using Nona-3 (N-
sulfation at the nonreducing end) and Nona-7 (N-acetylation at the nonreducing and reducing 
end). In a processive model, the enzyme binds the substrate and catalyzes a series of similar 
chemical reactions along that substrate before releasing to solvent the terminally degraded 
product. In a nonprocessive model, the enzyme cleaves one susceptible linkage, releases the 
product, and becomes available to interact with an new substrate.  If the enzyme cleaves only 
once before releasing the substrate, intermediates should be observed in the reaction [234].  
We utilized a classic model to study this degradative enzyme by partially digesting the 
substrates with enzyme and analyzing the cleavage products over time. The characteristic 
used to distinguish processive degradation were as follows: If the only products were high 
molecular weight substrate (that is, starting material) and final product were observed, then 
the enzyme was considered to act processively [235]. However, if intermediate was produced 
in the reaction before the final product appeared then the reaction was considered 
nonprocessive [234].  
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We compared the digestion time course for Nona-3 and Nona-7 using 
35
S-labeled substrates 
as well as the unlabeled substrates. The reaction conditions were substoichiometric with 
160X less enzyme than substrate. Using 
35
S-labeled Nona-3 substrate, different 
35
S-peaks 
emerged as the digestion proceeded via DEAE-HPLC analysis (Figure 47A), whereas, a 
decrease in the intensity of the 
35
S-peak eluted at 47 min from DEAE-HPLC, representing 
the starting substrate, was decreased.  For example, two 
35
S-labeled peaks, which were eluted 
at 16 and 42 mins from DEAE-HPLC column, were observed when heparanase and the 
substrate were incubated for 25 min.  As the incubation time extended, the intensity of 
35
S-
labeled peak eluted at 42 min decreased, and an additional 
35
S-labeled peaked emerged at 14 
min (Figure 47A).  Very similar profiles were obtained when Nona-7 was incubated with 
heparanase at similar time intervals (Figure 47B).  These data suggest that intermediate 
oligosaccharides were formed during the digestion. 
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Figure 47.  DEAE-HPLC chromatograms of 
35
S-labeled Nona-3 and Nona-7 digested with heparanase at 
different time.  Heparanase was incubated with 
35
S-labeled Nona-3 and Nona-7 at 0, 5, 15, 25, 60, 120, 240, 
480 mins.  The reaction was stopped and the cleavage products were analyzed and separated by high resolution 
DEAE-HPLC. Panel A shows the degradation of 
35
S-labeled Nona-3 and Nona-7 from 0-480 min by 
heparanase. Panel B (top) is a schematic that identifies the cleavage products from the chemical reaction 
involved in the digestion of Nona-3 with heparanase. Panel B (bottom) shows the chemical reaction involved in 
the digestion of Nona-7 with heparanase. 
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Figure 48. Partial digestion of unlabeled Nona-3. Unlabeled Nona-3 was partially degraded by heparanase for 
30 min. Panel A shows the ESI-MS spectra of partially heparanase-digested Nona-3 of fractions eluted from P-2 
column. The left panel shows the spectrum of Nona-3 and Hexa (PNP)-18 from fraction 34. The right panel 
shows the spectrum of Tri-12 from fractions 40 but also contain Nona-3 and Hexa (PNP)-18.Panel B shows the 
chemical reaction involved in the partial digestion of Nona-3 with heparanase. 
 
Next, we sought to determine the structures of the intermediates that resulted from 
partial digestions of unlabeled Nona-3 and Nona-7 by heparanase.  For Nona-3, the digestion 
was stopped at 30 min, and the products were analyzed by ESI-MS (Figure 48).   Two 
products were identified: Tri-12 and Hexa (PNP)-18.  Our results indicate that heparanase 
cleaves the glycosidic bond of Nona-3 that is located more close to the nonreducing end.  For 
Nona-7, the digestion with heparanase was also stopped at 30 min, and the products were 
subjected to ESI-MS analysis (Figure 49).  Two oligosaccharides were identified: Tri-13 and 
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Hexa-(PNP)-19.  Hence, our data suggest that heparanase cleaves the glycosidic bond more 
close to the nonreducing end to release a trisaccharide and a hexasaccharide.  The resultant 
hexasaccharide was subsequently digested to the final products.  Although both the digestion 
of Nona-3 and Nona-7 followed a similar degradation pathway, the initial rate at the first step 
digestion from nonasaccharide to hexasaccharide is significantly different.  A significant 
portion of Nona-3 remained after 25 min digestion, while only 15-20% of Nona-7 was 
present.  On the other hand, the later digestion step from hexasaccharide to tetrasaccharide, 
Hexa(PNP)-18 from Nona-3 disappeared much faster than Hexa(PNP)-19 from Nona-7. 
The results from the time course of the heparanase catalyzed reaction suggest that 
heparanase cleaves nonprocessively. In a nonprocessive reaction, it is assumed that the 
substrate has to associate with the enzyme multiple times to undergo complete degradation.  
Therefore, starting material and intermediate must compete for binding to the substrate to 
undergo degradation in a nonprocessive reaction [236]. This competition can be observed in 
the time course study (Figure 47). In the heparanase degradation reactions, the 
nonasaccharide starting material has to compete with the trisaccharide and hexasaccharide 
for binding to heparanase to undergo further degradation. As a result of heparanase cleavage 
size dependence, the intermediate in both reactions cannot be degraded into final product 
until all of the starting material is cleaved.  Thus, our results suggest that heparanase 
nonprocessively cleaves substrates in the guidelines of its size dependence.   
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Figure 49. Partial digestion of unlabeled Nona-7. Unlabeled Nona-7 was partially degraded by heparanase for 
30 min. Panel A shows the ESI-MS spectra of partially heparanase-digested Nona-7 of fractions eluted from P-2 
column. The left panel shows the spectrum of Nona-7 from fraction 35. The middle panel shows the spectrum 
of Tri-13 from fraction 44. The right panel shows the spectrum of Hexa (PNP)-19 from fraction 40. Panel B 
shows the chemical reaction involved in the partial digestion of Nona-7 with heparanase. 
 
Section 6. Conclusion 
Heparanase is reportedly involved in a wide range of pathophysiological functions, 
including stimulating tumor metastasis, inflammatory responses and autoimmune-mediated 
cellular damages [237].  These diversified functions of heparanase are predominantly 
attributed to the release of short HS fragments resulted from the action of heparanase on HS 
present in the ECM. The degraded HS fragments bind to different growth factors and 
chemokines that regulate a series of cellular events. Therefore, understanding the substrate 
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specificity of heparanase is essential for deciphering the roles of heparanase in regulating or 
progressing diseases at the molecular levels.   
In this study, we employed a selective library of oligosaccharides coupled with ESI-
MS analysis to determine the substrate specificity of heparanase.  Although HS has complex 
saccharide sequences, the current study was only focused on the substrates containing the 
disaccharide repeating unit of –GlcUA-GlcNS6S- and –GlcUA-GlcNAc6S-.  This selection 
is based on the fact that –GlcUA-GlcNS6S- is known to be the site cleaved by heparanase 
[202, 203, 207].  The structural domain of –IdoUA2S-GlcNS±6S- (heparin) was not included 
in the current study because this repeating unit is resistant to heparanase digestion [187, 212].  
We also chose to synthesize the oligosaccharides containing the disaccharide units of –
GlcUA-GlcNAc6S-, permitting us to examine the effects of the GlcNAc6S residue on the 
substrate specificity.  Collectively, the utilization of these substrates provided the opportunity 
to examine the substrate specificity of heparanase in greater details.  We discovered that 
heparanase cleaves both the linkages of -GlcUA-GlcNAc6S and -GlcA-GlcNS6S-.  The 
susceptibility of the linkage –GlcUA-GlcNAc6S- to heparanase cleavage is somewhat 
surprising as it was concluded to be resistant to heparanase cleavage using a synthetic 
polysaccharide substrate, which contains the linkages of –GlcUA-GlcNAc- or –GlcUA-
GlcNAc6S- (but not –GlcUA-GlcNS6S-) [207].  The discrepancy is likely due to the fact that 
the presence of –GlcUA-GlcNS6S- in the nearby renders heparanase susceptible to the 
linkage of –GlcUA-GlcNAc6S- .   
Our data indicate that heparanase is able to degrade the substrates in two modes: 
consecutive cleavage and gapped cleavage (Figure 46).  In the consecutive cleavage mode, 
heparanase removes three saccharide residues from the nonreducing end followed by 
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removing two additional residues from the nonreducing end.  In the gapped cleavage mode, 
heparanase also removes the three saccharide residues from the nonreducing end and skips 
the immediate next cleavage site, leaving a bigger fragment from the internal portion of the 
substrate.  Heparanase displays consecutive cleavage mode when a GlcNAc6S is present in 
the nonreducing end trisaccharide domain; whereas it displays a gapped cleavage mode when 
the GlcNAc6S is replaced by a GlcNS6S residue.  However, we are unsure if the 
trisaccharide domain from the nonreducing end serves as a modulator to direct heparanase to 
display consecutive or gapped cleavage mode.  Because our data showed that heparanase 
releases the nonreducing end trisaccharide first before it further degrades the substrate, the 
latter mechanism might warrant further investigation.  
Collectively, these findings revealed a unique control mechanism for the action of 
heparanase.  Our result should advance the understanding of the regulation of HS 
biosynthesis and the intimate relationship between HS and heparanase.  Further investigation 
on the mechanism to direct the cleavage of heparanase will aid to decipher the wide ranges of 
pathophysiological functions of heparanase in vivo. 
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Chapter VI  
CONCLUSION 
Heparanase is a glucuronidase that degrades one of the most fundamental 
polysaccharides within the body [1]. The degradation by heparanase results in the release of 
smaller fragments that may bind to specific ligands to modulate their biological activity or 
prevent the association of proteins that would be deleterious to the cell. Despite the purpose 
of degradation, the actions of heparanase play a fundamental role in regulating several 
pathophysiological processes such as tissue remodeling, inflammation, angiogenesis, 
metastasis, and tumor progression. Thus, defining the structural features of HS that direct 
heparanase cleavage may be essential for understanding how the binding of proteins can be 
modulated to regulate disease states. However, several challenges are associated with 
understanding the interaction between HS and heparanase. For example, understanding this 
interaction has been limited by the heterogeneity of substrates and the lack of techniques to 
synthesize structurally defined oligosaccharides or polysaccharides with defined sulfation 
types to probe heparanase specificity. Therefore, we sought to determine the features of HS 
that alter heparanase cleavage to uncover how HS structure may regulate heparanase activity. 
Although it was initially believed that heparanase recognized a defined sequence, 
here we report that heparanase recognizes key sulfation types. Utilizing chemo-enzymatically 
synthesized polysaccharide substrates with unique sulfation patterns, we were able to dissect 
the structural moieties required for heparanase cleavage. Our data suggest that heparanase 
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that heparanase cleaves the linkage between a GlcUA unit and an N-sulfo glucosamine unit 
carrying either a 3-O-sulfo or a 6-O-sulfo group. In addition, heparanase cleaves the linkage 
of a GlcUA unit and N-sulfo glucosamine unit with a 2-O-sulfated GlcUA residue, not a 2-O-
sulfated IdoUA residue, in proximity. We also discovered that the polysaccharide with 
repeating disaccharide units of IdoUA2S-GlcNS inhibits the activity of heparanase. 
Moreover, the utilization of a selective library of oligosaccharides coupled with ESI-MS 
analysis and large quantities of a pure enzyme provided the opportunity to examine the 
substrate specificity of heparanase in greater detail.  We determined that heparanase utilizes 
key structural features within HS to cleave endolytically, initiating cleavage at the 
nonreducing end.  
Furthermore, our data indicates that heparanase cleavages these structurally unbiased 
(GlcUA-GlcNS6S) substrates nonprocessively.  This reveals for the first time another layer 
of regulation for HS fragmentation by heparanase. At the polysaccharide level, heparanase 
cleavage is regulated by the sulfation type [207]. However, it can be inferred that at the 
oligosaccharide level where there is less diversity within sulfation type, the nonprocessive 
mode of action would be essential for the release of fragments of specific sizes. These 
findings advance the understanding of the substrate specificity of heparanase and identify a 
lead compound for developing polysaccharide-based heparanase inhibitors. Moreover, it 
revealed a unique control mechanism for the action of heparanase and advances the 
understanding of the regulation of HS biosynthesis and the intimate relationship between HS 
and heparanase.   
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Inhibitor Name Structure 
 
 
 
 
1. Heparin 
 
 
 
2. SST0001/ 
Glycol Split 
Heparin 
 
 
 
 
 
 
 
3. PI-88 
 
 
 
 
 
 
4. JG3 
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5. 1,3-bis-[4-
(1H-
benzoimida
zol-2yl)-
phenyl]-
urea 
 
 
6. OGS small 
molecule 
inhibitors 
(lead 
compound) 
R1=H, MeO   
                                               R2= H, Me, Ph 
a. The glycol split structure is from [181]. 
b. PI-88 structure is from [238]. 
c. JG3 structure is from [192]. 
d. 1,3-bis-[4-(1H-benzoimidazol-2yl)-phenyl]-urea structure is from [199]. 
e. OGS lead compound is from [62]. 
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